imipramine profile

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

imipramine is involved in 3 pathway(s), involving a total of 47 unique proteins and 65 unique compounds

ID Source	ID
PubMed CID	3696
CHEMBL ID	11
CHEBI ID	47499
SCHEMBL ID	34282
MeSH ID	M0011056

Synonym
janimine
BIDD:GT0116
AB00053486-15
BRD-K38436528-003-05-5
gtpl357
2,2'-(3-dimethylaminopropylimino)bibenzyl
n-(3-dimethylaminopropyl)-o-iminodibenzyl
5h-dibenz(b, 5-(3-(dimethylamino)propyl)-10,11-dihydro-
2,2'-(3-dimethylaminopropylimino)dibenzyl
1-(3-dimethylaminopropyl)-4,3,6,7-dibenzazepine
timolet
n-(.gamma.-dimethylaminopropyl)iminodibenzyl
dynaprin
imizine
imizin
5-(3-(dimethylamino)propyl)-10,f)azepine
psychoforin
melipramin
nsc-169866
intalpram
promiben
imiprin
tofranil, base
nelipramin
antideprin
5,e)azepine
berkomine
censtin
imidobenzyle
wln: t c676 bn&t&j b3n1&1
5h-dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
5h-dibenz[b, 10,11-dihydro-n,n-dimethyl-
censtim
5,e]azepine
dpid
impramine
imizinum
iramil
eupramin
irmin
tofranil (free base)
sk-pramine
surplix
dimipressin
5h-dibenz(b, 10,11-dihydro-5-(3-(dimethylamino)propyl)-
nsc169866
5-(3-dimethylaminopropyl)-10,f)azepine
imavate
melipramine
dyna-zina
5h-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-
DIVK1C_000559
KBIO1_000559
einecs 200-042-1
5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz(b,f)azepine
hsdb 3100
5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-
imipramina [inn-spanish]
ccris 9173
brn 0256892
5-(3-dimethylaminopropyl)-10,11-dihydro-5h-dibenzo(b,f)azepine
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-
nsc 169866
5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine
imipraminum [inn-latin]
imipramina [italian]
5h-dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-
imipramine [inn:ban]
1-(3-dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine
SPECTRUM_000915
NCGC00015563-01
lopac-i-7379
NCGC00015563-02
cas-113-52-0
BPBIO1_000313
BSPBIO_000283
IDI1_000559
PRESTWICK2_000072
BSPBIO_002172
PRESTWICK3_000072
LOPAC0_000702
SPECTRUM5_000864
AB00053486
C07049
50-49-7
imipramine
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethyl-propan-1-amine
10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
tofranil (hydrochloride)
janimine (hydrochloride)
DB00458
tofranil (tn)
10,11-dihydro-5-(3-(dimethylamino)propyl)-5h-dibenz[b,f]azepine
OPREA1_200908
imipraminum
CHEBI:47499 ,
NCGC00024253-04
imipramin
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
n-(gamma-dimethylaminopropyl)iminodibenzyl
3-(5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenz[b,f]azepine
KBIO3_001392
KBIO2_003963
KBIO2_006531
KBIO2_001395
KBIOGR_000391
KBIOSS_001395
SPBIO_002204
SPBIO_001059
PRESTWICK1_000072
PRESTWICK0_000072
NINDS_000559
SPECTRUM3_000466
SPECTRUM2_000990
SPECTRUM4_000016
NCGC00015563-03
NCGC00024253-03
inchi=1/c19h24n2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11h,7,12-15h2,1-2h
HMS2089G08
NCGC00015563-09
L000739
sermonil
trimipramine maleate impurity, imipramine-
cristalia
org-2463
CHEMBL11 ,
D08070
imipramine (inn)
bdbm50010859
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine
NCGC00015563-07
ixx ,
tox21_110174
cas-50-49-7
dtxsid1043881 ,
dtxcid9023881
declomipramine
AKOS016010320
CCG-36485
NCGC00015563-11
NCGC00015563-08
NCGC00015563-06
NCGC00015563-04
NCGC00015563-05
NCGC00015563-10
FT-0670319
unii-ogg85sx4e4
imipramina
ogg85sx4e4 ,
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine
imipramine [mart.]
trimipramine maleate impurity, imipramine- [usp impurity]
imipramine [vandf]
imipramine [who-dd]
imipramine [mi]
clomipramine hydrochloride impurity b [ep impurity]
imipramine [hsdb]
imipramine [inn]
trimipramine maleate impurity d [ep impurity]
SCHEMBL34282
NCGC00015563-13
tox21_110174_1
surplix (salt/mix)
5h-dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
imizinum (salt/mix)
tofranil (salt/mix)
eupramin (salt/mix)
imizine (salt/mix)
imavate (salt/mix)
imizin (salt/mix)
psychoforin (salt/mix)
sk-pramine (salt/mix)
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine #
g-22355 (salt/mix)
W-109253
STL416211
AB00053486_17
AB00053486_16
FT-0697093
(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
tofranil base
MRF-0000592
SBI-0050680.P004
3-(10,11-dihydro-5h-dibenz[b,f]azepin-5-yl)propyldimethylamine
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine;3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
112898-42-7
SY246340
2241983-10-6
mfcd31699979
n,n-dimethyl-10,11-dihydro-5h-dibenzo[b,f]azepine-5-propanamine-2,8-d2
clomipramine ep impurity b; 10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
Q58396
BRD-K38436528-003-15-4
SDCCGSBI-0050680.P005
NCGC00015563-25
EN300-708790
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
HY-B1490A
CS-0013621
imipramine-d3 hydrochloride 98 atom % d
3-(5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine
trimipramine maleate impurity, imipramine-(usp impurity)
10,11-dihydro-n,n-dimethyl-5h-dibenz(b,f)azepine-5-propanamine
imipramina (inn-spanish)
imipraminum (inn-latin)
trimipramine maleate impurity d (ep impurity)
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine
imipramine (mart.)
n06aa02

Excerpt	Reference
"Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer."	( Chen, SK; Chen, WT; Hsu, FT; Lee, W; Li, YC, 2023)
"Imipramine (IMI), which is a tricyclic antidepressant, has also been shown to has antineoplastic effect."	( Barlaz Us, S; Comelekoglu, U; Sogut, F; Yalin, S; Yetkin, D; Yildirim, M; Yilmaz, SN, 2019)
"Imipramine (IMI) is a frequently prescribed tricyclic antidepressant and widely detected in the natural waters, while the environmental fate of IMI is yet poorly understood. "	( Chen, Y; Fang, Y; Grivin, VP; Liu, L; Luo, F; Parkhats, MV; Pozdnyakov, IP; Tyutereva, YE; Wan, D, 2020)
"Imipramine (IMI) is a tricyclic synthetic antidepressant that is used to treat chronic psychiatric disorders, including depression and neuropathic pain. "	( Kim, MJ; Kim, YT; Lim, EY; Park, J, 2020)
"Imipramine is an antidepressant that increases the release of neurotransmitters."	( Aldubayan, M; Alhowail, A; Chigurupati, S; Elgharabawy, R, 2020)
"Imipramine is a tricyclic antidepressant used to treat enuresis with initial success rates are high as 50% but some studies record a high relapse rate and it has a cardiotoxic effect when overdosed."	( Elawady, H; Mahmoud, MA; Samir, M, 2021)
"Imipramine is a kind of tricyclic antidepressant with reported anti-inflammatory and anti-oxidant effects in the brain."	( Ahmadiani, A; Askari, S; Dargahi, L; Ghasemi, R; Javadpour, P; Rashidi, FS, 2021)
"Imipramine is a tricyclic antidepressant (TCA) drug that is sometimes used to treat neuropathic pain. "	( Khakpai, F; Ramezanikhah, M; Valizadegan, F; Zarrindast, MR, 2021)
"Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics."	( Biswas, R; Harkema, JR; Holian, A; Jessop, F; Trout, KL, 2017)
"Imipramine is a tricyclic medication that has been used for the treatment of depression and other mood disorders. "	( Bicknell, LM; Fernandez, M; McFaddin, CL; Parekh, P, 2017)
"Imipramine is a tricyclic antidepressant inhibitor of norepinephrine and serotonin neuronal reuptake. "	( Pupo, AS; Ribeiro, CA, 2015)
"Imipramine blue (IB) is a newly identified anti-invasive compound that effectively inhibits glioma invasion."	( Arbiser, JL; Hsu, WH; Su, YH; Wang, CC; Yang, MH; Yang, WH, 2016)
"Imipramine seems to be a better cost-utility antidepressant option for treating depressive disorders in primary care."	( Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2009)
"Imipramine is a tertiary amine, which may act both in the periphery and/or pass through the blood-brain barrier (BBB) in unionized form and exhibit a central effect."	( Faizi, M; Jamali, B; Kobarfard, F; Roodsari, MS; Shafaghi, B; Soleymani, Z, 2009)
"Imipramine is a commonly used tricyclic antidepressant (TCA)."	( Farahvar, A; Han, X; Huang, JH; Samadani, U; Smith, DH; Tong, J; Wang, E; Yang, J; Zhang, J, 2011)
"Imipramine is a useful treatment for enuresis when everything else has failed, especially among older children. "	( Gepertz, S; Nevéus, T, 2004)
"Imipramine (IP) is an amphiphilic amine that is clinically useful as a tricyclic antidepressant. "	( Ahyayauch, H; Bennouna, M; Goñi, FM, 2004)
"Imipramine is a well-established tricyclic antidepressant which was first approved for the treatment of depression in the late fifties. "	( Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Kadasah, S; Tariq, M, 2005)
"Imipramine is a rare cause of gray-blue facial pigmentation. "	( Lin, AN; Metelitsa, AI; Nguyen, GK, 2005)
"Imipramine is an effective antiarrhythmic agent against ventricular arrhythmias and complex features of ventricular premature depolarizations at plasma concentrations ranging from 100 to 400 ng per ml. "	( Giardina, EG, 1984)
"Imipramine is an effective antiarrhythmic drug with sustained duration of action, although its elimination t1/2 is relatively short."	( Alchevsky, D; Bigger, JT; Brem, R; Giardina, EG; Louie, M, 1983)
"Imipramine is a tricyclic antidepressant drug that also exhibits antiarrhythmic effects and whose clinical spectrum of activity is similar to that of quinidine. "	( Delpón, E; Elizalde, A; Pérez, O; Sánchez-Chapula, J; Tamargo, J; Valenzuela, C, 1994)
"Imipramine is an effective antidepressant agent that blocks the reuptake of monoamines. "	( Hoffman, T; Jiménez-Rivera, CA; Santacana, G; Savage, DD; Segarra, O; Weiss, GK, 1996)
"Imipramine is an antidepressant drug that is rarely associated with mild liver function abnormalities. "	( Ilan, Y; Reynes, M; Samuel, D; Tur-Kaspa, R, 1996)
"Imipramine is a tricyclic antidepressant known to be bound in the serum primarily by alpha-1-acid glycoprotein. "	( Baumann, H; Dewey, MJ; Fincher, TK; Holladay, JW; Yoo, SD, 1996)
"Imipramine is a tricyclic antidepressant drug with a considerable hepatic first-pass metabolism resulting in highly variable pharmacokinetic characteristics and desipramine as active major metabolite. "	( Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001)
"Imipramine (IMP) is a biologically active amine which is removed from the circulation by the lungs. "	( Block, ER; Cannon, JK, 1978)
"Imipramine is an established treatment for anxiety in adults. "	( Kanner, AM; Klein, RG; Mascia, A; Rubinstein, B, 1989)
"Imipramine probably acts as a protonophore by increasing the rate of proton-gradient dissipation rather than by interfering with the hydrogen-pump system because, in gastric membranes, imipramine was 20-fold less potent than omeprazole in inhibiting the gastric H-K-adenosine triphosphatase activity."	( Batzri, S; Brugada, O; Harmon, JW; Rich, NM, 1988)
"Imipramine is a tricyclic antidepressant that has been demonstrated to be useful in the treatment of certain voiding dysfunctions. "	( Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988)
"Imipramine methiodide is a quaternary derivative of imipramine which does not cross the blood-brain barrier easily."	( Frances, H; Simon, P, 1985)

Excerpt	Reference
"Imipramine has a diphenyl structural motif almost identical to that in carbamazepine (a dibenzazepine tricyclic compound), as well as a tertiary amine chain similar to that in many prototypical local anesthetics, and has also been reported to inhibit Na(+) channels in a use-dependent fashion."	( Kuo, CC; Yang, YC, 2002)
"Imipramine has a proven effect in enuresis but is now seldom used. "	( Gepertz, S; Nevéus, T, 2004)
"Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases."	( Nevéus, T; Tullus, K, 2008)
"Imipramine has a vasopressin independent antidiuretic effect if nocturnal polyuria is present. "	( Djurhuus, JC; Hunsballe, JM; Olesen, OV; Pedersen, EB; Rittig, S, 1997)
"Imipramine has a documented effect on such pain conditions on temporal summation."	( Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001)
"Imipramine has a role in patients who achieve partial continence after reconstruction, and who have a moderately small capacity bladder with poor compliance and uninhibited contractions."	( Agarwala, S; Bhatnagar, V; Dave, S; Grover, VP; Mitra, DK, 2002)
"Imipramine has a direct membrane action."	( Fozzard, HA; Rawling, DA, 1979)
"Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%)."	( Gram, LF, 1988)
"Imipramine has a variety of pharmacological effects including direct antimuscarinic activity, inhibition of catecholamine reuptake, direct muscle relaxant, and calcium antagonism."	( Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988)
"Imipramine has been widely used as an antidepressant in the clinic over the years. "	( Bobula, B; Stachowicz, K; Tokarski, K, 2020)
"Imipramine has been suggested as a treatment for antipsychotic-associated RE in one small study of patients prescribed thioridazine and a case series of patients prescribed iloperidone."	( Lyall, M; Roughley, M, 2019)
"Imipramine has been surpassed by newer antidepressants for the treatment of depression in the past decade."	( Cheung, KL; Fung, CK; Hon, KL; Lee, VW; Leung, AK; Wong, W, 2015)
"Imipramine has been used for over four decades (early reports in 1960s) for the treatment of nocturnal enuresis, although the reason for its effect is not clear. "	( Faizi, M; Jamali, B; Kobarfard, F; Roodsari, MS; Shafaghi, B; Soleymani, Z, 2009)
"Imipramine (IM) has been widely used in clinics for the treatment of some mental diseases. "	( Li, H, 2012)
"Imipramine (IM) has been widely used clinically for the treatment of mental disorders. "	( Cai, G; Chen, Y; Fong, CC; Li, H; Yang, M, 2012)
"Imipramine and doxepin have been reported to exhibit local anaesthetic properties."	( Campmany, AC; Campos, FF; Naveros, BC; Sandig, AG; Villena, MJ, 2013)
"Imipramine has a diphenyl structural motif almost identical to that in carbamazepine (a dibenzazepine tricyclic compound), as well as a tertiary amine chain similar to that in many prototypical local anesthetics, and has also been reported to inhibit Na(+) channels in a use-dependent fashion."	( Kuo, CC; Yang, YC, 2002)
"Imipramine has a proven effect in enuresis but is now seldom used. "	( Gepertz, S; Nevéus, T, 2004)
"Imipramine has often been used as positive control in studies investigating the efficacy of new antidepressants. "	( Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005)
"Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases."	( Nevéus, T; Tullus, K, 2008)
"Imipramine has proven effective in reducing binging episodes, and further evaluation of antidepressants seems warranted."	( Conner, CS, 1983)
"[3H]imipramine has been proposed as a specific label for serotonin uptake sites in brain."	( Morin, R; Vint, CK; Whitaker, PM, 1983)
"Imipramine has a vasopressin independent antidiuretic effect if nocturnal polyuria is present. "	( Djurhuus, JC; Hunsballe, JM; Olesen, OV; Pedersen, EB; Rittig, S, 1997)
"Imipramine has proven efficacy for panic disorder. "	( Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998)
"Imipramine has been shown to reduce anxiety in patients with generalized anxiety disorder (GAD). "	( Clark, CM; Hoehn-Saric, R; Kowalski, PA; McLeod, DR; Porges, SW, 2000)
"Imipramine has a documented effect on such pain conditions on temporal summation."	( Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001)
"Imipramine has a role in patients who achieve partial continence after reconstruction, and who have a moderately small capacity bladder with poor compliance and uninhibited contractions."	( Agarwala, S; Bhatnagar, V; Dave, S; Grover, VP; Mitra, DK, 2002)
"Imipramine has a direct membrane action."	( Fozzard, HA; Rawling, DA, 1979)
"Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%)."	( Gram, LF, 1988)
"Imipramine has a variety of pharmacological effects including direct antimuscarinic activity, inhibition of catecholamine reuptake, direct muscle relaxant, and calcium antagonism."	( Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988)
"Imipramine has been reported as significantly more effective against panic attacks than placebo or other psychoactive drugs in 12 of 16 studies."	( Modigh, K, 1987)

Excerpt	Reference
"The imipramine-induced BDNF increase was suppressed with inhibitors for protein kinase A (PKA) or MEK/ERK."	( Kawabe, K; Moriyama, M; Nakamura, Y; Takano, K; Yamasaki, H, 2012)
"Imipramine promotes the non-amyloidogenic route of APP processing via stimulatory effects on PKC."	( Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005)
"Imipramine is a rare cause of gray-blue facial pigmentation. "	( Lin, AN; Metelitsa, AI; Nguyen, GK, 2005)
"Imipramine did not inhibit the acute phosphorylation of TH at Ser40 or TH activation induced by nicotine, but did inhibit the sustained responses to nicotine seen at 24 h."	( Bobrovskaya, L; Bolster, EK; Dickson, PW; Dunkley, PR; Flaherty, JJ; Gilligan, C, 2007)
"Imipramine was used to inhibit the serotonin uptake mechanism."	( Dawson, CA; Linehan, JH; Rickaby, DA, 1984)
"Imipramine caused an increase in 3H-DA efflux and this imipramine-induced efflux is Ca2+-independent."	( Kamiya, H; Kohjimoto, Y; Saito, R; Sakurai, Y; Takano, Y, 1981)
"Imipramine did increase sitting and standing heart rate without revealing a clear dosage correlation."	( de Groot, CM; Mavissakalian, MR, 1994)
"Imipramine caused an increase in the GH ratio in all subgroups."	( Franz, B; Grochocinski, VJ; Jarrett, DB; Kupfer, DJ; Miewald, JM, 1995)
"Imipramine did not cause significant changes in pain perception during the cold pressor test."	( Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001)

Excerpt	Reference
"Imipramine treatment caused diminished ovarian reserve and atretic follicle; however, agmatine treatment provided the maintenance of ovarian follicular reserve after MS."	( Arıcıoğlu, F; Önel, T; Yaba, A; Yıldırım, E; Zortul, H, 2023)
"Imipramine treatment compared with placebo significantly improved overall health in patients with multiple functional somatic syndromes when both treatments were supported by regular contacts with clinicians. "	( Agger, JL; Fink, PK; Gormsen, LK; Jensen, JS; Jensen, TS; Schröder, A, 2017)
"Imipramine treatment was able to reverse depressive- and anxiety-like behaviors."	( Barichello, T; Ceretta, RA; Dal-Pizzol, F; Dominguini, D; Generoso, JS; Michels, M; Netto, S; Réus, GZ; Simões, LR; Valim, RF; Valvassori, SS, 2019)
"Imipramine treatment reversed the UCMS-induced alterations of the coat state (BALB/c, DBA), in the NSF test (A/J, BALB/c, C57BL/6) and in fecal corticosterone metabolites (BALB/c, C57BL/6)."	( Belzung, C; Ibarguen-Vargas, Y; Palme, R; Surget, A; Touma, C, 2008)
"Imipramine treatment caused increased plasma concentration of all amino acid, except for L-aspartate and taurine."	( Furuse, M; Murakami, T; Tomonaga, S; Yamane, H, 2009)
"Imipramine treatment significantly increased the number of neurons in the granule cell layer (GCL) and spine synapses in the CA1 in the FSL imipramine group (treated "depressed" rats) compared with the FSL saline group."	( Chen, F; Madsen, TM; Nyengaard, JR; Wegener, G, 2010)
"Imipramine treatment at 5 and 20 mg/kg/d enhanced BNIP3 mRNA expression only in the LH group but not in non-LH group or non-stressed group."	( Matsumoto, K; Mingmalairak, S; Murakami, Y; Tohda, M, 2010)
"Imipramine treatment did not affect this factor."	( Cieślik, K; Legutko, B; Nowak, G; Opoka, W; Ossowska, G; Sowa-Kućma, M; Wolak, M, 2011)
"Imipramine treatment hit 13 disease clusters: tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, precipitation of congestive heart failure; urinary retention, altered liver functions."	( Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012)
"Imipramine treatment decreased anxiety levels in females, but not in males, in the normal weaning condition. "	( Kikusui, T; Mogi, K; Nagasawa, M; Shimokawa, Y, 2012)
"Imipramine treatment in depression might exert antidepressant action through BDNF production from astrocytes, and glial BDNF expression might be a target of developing novel antidepressants."	( Kawabe, K; Moriyama, M; Nakamura, Y; Takano, K; Yamasaki, H, 2012)
"Imipramine treatment amplified the PI response to the non subtype-selective mGlu receptor agonist, 1S,3R-aminocyclopentane-1,3-dicarboxylated (1S,3R-ACPD) in both hippocampal and cortical slices, but failed to affect the response to the selective mGlu1/5 receptor agonist, S-3,5-dihydroxyphenylglycine (DHPG)."	( Cappuccio, I; Caricasole, A; Matrisciano, F; Melchiorri, D; Ngomba, RT; Nicoletti, F; Riozzi, B; Scaccianoce, S; Storto, M, 2002)
"Imipramine is a useful treatment for enuresis when everything else has failed, especially among older children. "	( Gepertz, S; Nevéus, T, 2004)
"Imipramine treatment (50 mg three times daily) in 7 subjects served as a positive control."	( Goldstein, DS; Haertter, S; Jordan, J; Luft, FC; Schroeder, C; Stoeter, M; Tank, J, 2004)
"Imipramine treatment further decreased harmaline-induced 5HT turnover in the brain stem."	( Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Kadasah, S; Tariq, M, 2005)
"Imipramine treatment offset all the behavioral and neurochemical stress-induced modifications."	( Cassanelli, A; Danielli, B; De Montis, MG; Raone, A; Rauggi, R; Scheggi, S, 2007)
"Imipramine treatment also resulted in a decrease of extracellular field potentials evoked in layer II/III by stimulation of underlying sites in layer V."	( Bobula, B; Hess, G; Tokarski, K; Wabno, J, 2008)
"Imipramine treatment was associated with significant improvement in both observer-rated and patient-rated depression scales."	( Barnes, R; Gumbrecht, G; Raskind, M; Veith, R, 1982)
"The imipramine treated group were significantly older."	( Montgomery, DB; Montgomery, SA; Robinson, C; Roy, D; Wynne-Willson, S, 1983)
"3 Imipramine (Imip) pretreatment before the second trial (10 mg/kg i.p on the 3 preceding days, and 2.5 mg/kg 1 h before) abolished these correlations."	( Harrison-Read, PE; Steinberg, H, 1980)
"The imipramine-treatment group failed to have either earlier response or better final outcome."	( Albala, AA; Carroll, BJ; Feinberg, M; Gardner, R; Greden, JF; Kronfol, Z; Mukhopadhyay, S, 1981)
"The imipramine pretreatment reversed the tetrabenazine-induced sedation."	( Hori, A; Kariya, T; Nakagawara, M; Watanabe, A, 1983)
"Imipramine treatment was maintained on a daily basis during the 7 days taken to complete the series of tests."	( Blanchard, DC; Blanchard, RJ; Magee, L; Rodgers, RJ; Shepherd, JK, 1993)
"Imipramine treatment elicited a marked decrease in beta 1 binding in the outer laminae of the cingulate cortex, as well as in the motor and somatosensory areas of the frontal cortex."	( Hietala, J; Kuoppamäki, M; Laakso, A; Pälvimäki, EP; Syvälahti, E, 1994)
"The imipramine-treated patients showed a higher frequency of adverse events, especially the anticholinergic type, than citalopram-treated patients."	( Damsbo, N; Fuglum, E; Horsgård, S; Jacobsen, LV; Rosenberg, C, 1994)
"Imipramine-treated patients reported more anticholinergic side effects, whereas tiredness and headache were observed more frequently in the moclobemide-treated patients."	( Jääskeläinen, J; Kaartinen, P; Kalli, A; Kilponen, E; Koskinen, T; Nikkilä, H; Pirttiperä, V; Rimón, R; Seppälä, J, 1993)
"Imipramine treatment did not affect the rate of reentrainment after a 6-h advance in the light-dark cycle, did not alter the advanced-phase angle of entrainment of tau-mutant hamsters, did not affect the free-running period of wild type hamsters, and did not alter the phase-response curve to light pulses."	( Menaker, M; Refinetti, R, 1993)
"Imipramine pretreatment did not change the immunochemically determined content of the CYP2D protein, suggesting that CYP2D is inactivated."	( Fujio, N; Funae, Y; Horie, T; Imaoka, S; Masubuchi, Y; Narimatsu, S; Suzuki, T; Takahashii, C, 1995)
"Imipramine treatment was safe and associated with improvement in depression in both adequately treated and intention-to-treat samples. "	( Agosti, V; Goldman, D; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JW, 1996)
"Imipramine treatment is effective for primary depression among actively drinking alcoholic outpatients, and may improve alcoholic outcome for those whose depression responds to treatment."	( Agosti, V; Goldman, D; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JW, 1996)
"Imipramine treatment was not significantly better than placebo for improvement in depression and anxiety ratings in this patient group."	( Zajecka, JM, 1996)
"Imipramine treatment resulted in a significant 15% increase in heart rate on both day 14 and day 28, whereas heart rate tended to decrease under venlafaxine."	( Benkert, O; Gründer, G; Schlösser, R; Wetzel, H, 1996)
"Imipramine treatment resulted in reductions in the duration of immobility in both transgenic (130 +/- 21 sec) and control (54 +/- 33 sec) mice."	( Baumann, H; Dewey, MJ; Fincher, TK; Holladay, JW; Yoo, SD, 1996)
"Imipramine (IMI) treatment yielded complete remission of her symptoms for three years."	( Nickell, PV, 1994)
"4. Imipramine treatment, either by daily injections or by subcutaneous implantation of slow release imipramine-containing polymers reduced the elevated tryptophan hydroxylase apoenzyme levels in the frontal cortex of bulbectomized, but not of sham-operated control rats and restored the deficient learning performance of bulbectomized rats."	( Becker, A; Franke, C; Grecksch, G; Huether, G; Sabel, B; Schröder, U; Zhou, D, 1997)
"Imipramine treatment, short- or long-term, did not alter the steady-state levels of GAT-1 mRNA."	( Baker, GB; Bateson, AN; Charrois, GJ; Lai, CT; Tanay, VA, 1998)
"Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings."	( Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999)
"Imipramine treatment diminished this response enhancement in CMS exposed animals, but did not alter the proliferative responses of control subjects."	( Arregi, A; Azpiroz, A; Beitia, G; Brain, PF; Cacho, R; Fano, E; Garmendia, L, 1999)
"Imipramine (IMI) treatment normalized tT4 values."	( Antoniou, K; Bekris, S; Christofidis, I; Kioukia, N; Papadopoulou-Daifoti, Z, 2000)
"Imipramine treatment produced only a slight decrease of food intake."	( Fonberg, E; Korczyński, R, 1979)
"Imipramine-treated platelets that were adherent to collagen showed significant depletion of metabolic ATP, but markedly diminished conversion of ATP to IMP as compared to control adherent platelets."	( Chen, AF; Morin, RJ, 1978)
"In imipramine-treated patients this finding was associated with a decreased rate of drug elimination from plasma."	( Cooper, TB; Friedman, MJ; Green, R; Ives, JO; Nies, A; Ravaris, CL; Robinson, DS, 1977)
"Imipramine pretreatment not only blocked the positive inotropic effect of propranolol but resulted in an exaggerated negative inotropic effect in both areas of the left ventricle along with a significant fall in systemic arterial blood pressure."	( Daniell, HB; Pierre, AJ; Webb, JG, 1976)
"Imipramine-treated patients were significantly more likely than those taking placebo to report one or more adverse effects, which were predominantly anticholinergic in nature."	( Fabre, LF, 1992)
"The imipramine-treated patients had superior global outcome."	( Alvir, JM; Bermanzohn, PC; Mason, SE; Rifkin, A; Siris, SG, 1992)
"In imipramine-treated rats the beta-down-regulation was still evident in the presence of TPA; after electroconvulsive treatment the phorbol ester-induced potentiation was so high that no significant beta-down-regulation could be observed."	( Nalepa, I; Vetulani, J, 1991)
"For imipramine-treated patients, high social support predicted a better response at 6 weeks, while development of hypomania during follow-up was associated with a better response at 6 weeks; absence of life events during the 6-month follow-up and initial non-suppression of dexamethasone predicted a better outcome at 6 months."	( Bulbena, A; Catalan, R; Gasto, C; Menchon, JM; Vallejo, J, 1991)
"In imipramine-treated animals LFES elicited much stronger contractions than in the controls."	( Todorov, S, 1990)
"Imipramine treatment decreased the peak value of 5-HT concentration at 1000 to about 65% and appears to abolish the rhythm of 5-HT concentration."	( Rotsch, M; Schulz, E; Wesemann, W; Zöfel, P, 1986)
"Imipramine treatment produced a down-regulation of the Bmax for 3H-dihydroalprenolol binding to cortical beta-adrenoceptors that was not dependent upon the time of day the animals were killed."	( Ask, AL; Fowler, CJ; Hall, H; Kelder, D; Ross, SB; Sääf, J, 1986)
"Imipramine treatment elicited a significantly greater decrease in these adrenergic sites in the aged (39.2%) than in the adult (27.6%) animals."	( Cooper, T; Friedman, E; Yocca, F, 1986)
"2. Imipramine treatment resulted in an increase in state 3 respiration rates with all the substrates tested as early as one week after treatment; this was sustained through the second week of treatment."	( Katyare, SS; Rajan, RR, 1988)
"Imipramine-treated patients reported the most and placebo patients the least number of adverse effects."	( Amsterdam, JD; Chung, HR; Csanalosi, IB; Hurowitz, AM; Kaplan, M; London, J; Rickels, K; Wiseman, K, 1987)
"Oral imipramine treatment (100 to 600 mg, twice daily) led to frequent erection and masturbation while at rest in the stall in a nonsexual context."	( Garcia, MC; Kenney, RM; McDonnell, SM; Van Arsdalen, KN, 1987)
"Imipramine treatment was attempted for nonoverweight patients with negative ear, nose and throat (ENT) findings and for patients who had not responded to weight reduction or ENT surgery (in all patients the apneas were not considered life threatening)."	( Alroy, GG; Lavie, P; Peled, R; Rubin, AH, 1986)
"Treatment with imipramine provided significant improvement of QoL by PP analysis (72±17 and 61±19, respectively; P=0.048), but ITT analysis did not reveal any differences between imipramine and placebo (68±19 and 61±19, respectively; P=0.26)."	( Charatcharoenwitthaya, P; Leelakusolvong, S; Limsrivilai, J; Pausawasdi, N, 2016)
"Treatment with imipramine, an ASMase inhibitor, inhibited the MF-induced EGFR clustering."	( Feng, B; Li, X; Sun, L; Sun, W; Wang, Y, 2016)
"On treatment with imipramine, wild-type mice became sedated and produced imipramine N-oxide in the brain and other tissues. "	( Chandan, P; Hernandez, D; Janmohamed, A; Omar, BA; Phillips, IR; Shephard, EA, 2009)
"The treatment with imipramine reversed all the parameters described above."	( Barichello, T; Cassol, OJ; Comim, CM; Constantino, LC; Constantino, LS; Dal-Pizzol, F; Kapczinski, F; Petronilho, F; Quevedo, J; Stertz, L, 2010)
"Pretreatment with imipramine (10 and 20mg/kg) and venlafaxine (5 and 10mg/kg) significantly reversed immobilized stress-induced behavioral and biochemical alterations."	( Garg, R; Gaur, V; Kumar, A; Kumar, P, 2009)
"Treatment with imipramine decreased the immobility time in nondiabetic and diabetic rats, compared with both nondiabetic and diabetic rats treated with saline."	( Aguiar, BW; Ceretta, LB; Kapczinski, F; Lersh, C; Pfaffenseller, B; Quevedo, J; Réus, GZ; Ribeiro, KF; Stringari, RB; Zappellini, G, 2012)
"Treatment with imipramine in the SD rats did not induce significant differences in the number of mitochondria."	( Chen, F; Madsen, TM; Nyengaard, JR; Wegener, G, 2013)
"Pretreatment with imipramine, buspirone, or placebo was compared in 40 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for panic disorder and in patients who were discontinuing long-term benzodiazepine use. "	( García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2003)
"Treatment with imipramine (3 x 30 mg/kg i.p.) induced a significantly shorter duration of immobility during the FST 5 min, but with no difference between ischemia and control rats."	( Allain, H; Amiot, N; Bantsiele, GB; Bentué-Ferrer, D; Bourin, M; Reymann, JM, 2004)
"Treatment with imipramine (10mg/kg i.p., once daily) commenced after experimental week 3."	( Antoniou, K; Bekris, S; Daskas, S; Papadopoulou-Daifoti, Z, 2005)
"Pretreatment with imipramine or CD14 blockade was associated with attenuation of all of these LPS-induced events."	( Billgrin, J; Bulger, E; Cuschieri, J; Garcia, I; Maier, RV, 2007)
"Treatment with imipramine decreased Stress-Sensitivity and increased Reward Experience (positive affect reactivity to positively appraised activities)."	( Barge-Schaapveld, DQ; de Vries, M; Mengelers, R; Nicolson, NA; Peeters, F; van Os, J; Wichers, MC, 2009)
"Treatment with imipramine hydrochloride decreased the number of sites, as measured with either ligand, in both patient groups and increased catecholamine levels in patients with panic attacks."	( Cameron, OG; Curtis, GC; Hollingsworth, PJ; Nesse, RM; Smith, CB, 1984)
"Treatment with imipramine showed 62.1% improvement (+/- s.d."	( Dreyfus, JF; Guelfi, JD; Pichot, P, 1983)
"Treatment with imipramine or chlorpromazine alone for 14 days decreased the density of 5-HT2 receptor binding sites in rat cortex; the combination of the two drugs produced a greater reduction in 5-HT2 binding sites than imipramine or chlorpromazine alone."	( Meltzer, HY; Mikuni, M, 1984)
"Treatment with imipramine and doxepin, but not placebo, was associated with significant improvement (P less than 0.001) in standard ratings of depression."	( Barnes, RF; Caldwell, JH; Gumbrecht, G; Raskind, MA; Ritchie, JL; Veith, RC, 1982)
"Rats treated with imipramine did not differ from those treated with saline on these parameters."	( Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996)
"Treatment with imipramine decreased auditory P300 latencies and increased auditory P300 amplitudes."	( Persky, B; Sangal, JM; Sangal, RB, 1996)
"Pretreatment with imipramine (30 mg/kg s.c.) significantly reduced the YM643- or sumiferon-induced increases in immobility time."	( Miyata, K; Yamano, M; Yasuda, S; Yuki, H, 2000)
"Treatment with imipramine is increasingly in disfavour because the relapse rate is unacceptably high and fatal overdose is a real possibility."	( Harari, MD; Moulden, A, 2000)
"Pretreatment with imipramine, MK 801 and ketamine significantly prevented the effect of shock."	( Bapna, JS; Chandra, D; Chaturvedi, HK, 1999)
"Treatment with imipramine resulted in a clinical improvement or cure in 16/22 patients (72.7%), with an average reduction in incontinent episodes of 78.7% (P<0.001)."	( Fischer, JR; Misko, CA; Woodman, PJ, 2001)
"Treatment with imipramine did not change the basal threshold of aversive electrical stimulation measured before intra-DPAG injection of the 5-HT agonists."	( Almeida, LP; Cabral, AH; Jacob, CA; Landeira-Fernandez, J; Magierek, V; Nogueira, RL; Ramos, PL; Zangrossi, H; Zanoveli, JM, 2002)
"Treatment with imipramine can reduce these behavioural changes but is only effective when given repeatedly prior to onset of CMS."	( Harkin, A; Houlihan, DD; Kelly, JP, 2002)
"Treatment with imipramine (1 mg/kg) after the whiplash is able to remove these behavioral and biochemical disturbances."	( Boismare, F; Le Poncin, M; Lefrançois, J, 1977)
"Pretreatment with imipramine resulted in 76% inhibition of the release reaction, but only 5% inhibition of adhesion."	( Chen, AF; Morin, RJ, 1978)
"When treatment with imipramine was terminated, vaginal cyclicity resumed within the next 2 to 8 days."	( Maswood, S; Uphouse, L, 1992)
"2. Treatment with imipramine (10 subjects) was associated with a significant decrease of T4 and FTI and treatment with diazepam (8 subject) was associated with a significant decrease of T4."	( Balon, R; Glitz, DA; Pohl, R; Ramesh, C; Yeragani, VK, 1991)
"Pretreatment with imipramine, desipiramine or fluvoxamine significantly potentiated the suppressant effect of d-amphetamine on responding; pretreatment with trazodone had no significant effect."	( Bradshaw, CM; Shah, K; Szabadi, E, 1990)
"Treatment by imipramine, desipramine, chlorpromazine, perphenazine and propericiazine 8 h before the administration with methamphetamine completely inhibited the urinary excretion of p-OH-MP whereas the excretion of amphetamine was enhanced by about 700 to 800%."	( Fujita, M; Kozuka, H; Mori, M, 1985)
"Treatment with imipramine inhibited metabolism of both sparteine and debrisoquine (MR values about doubled), but did not affect the interpatient correlations."	( Bech, P; Bertilsson, L; Brøsen, K; Gram, LF; Klysner, R; Otton, SV, 1986)

Role	Description
adrenergic uptake inhibitor	Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor	Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dibenzoazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Imipramine Action Pathway	35	21
Imipramine Metabolism Pathway	6	12
thyroid hormone metabolism II (via conjugation and/or degradation)	6	32

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
USP1 protein, partial	Homo sapiens (human)	Potency	35.4813	0.0316	37.5844	354.8130	AID504865
TDP1 protein	Homo sapiens (human)	Potency	21.5957	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	6.1143	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	0.5623	0.1800	13.5574	39.8107	AID1460
AR protein	Homo sapiens (human)	Potency	32.8670	0.0002	21.2231	8,912.5098	AID1259243; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	5.6234	0.0112	12.4002	100.0000	AID1030
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	0.9466	0.5318	15.4358	37.6858	AID504845
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	21.4552	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	29.8493	0.0030	41.6115	22,387.1992	AID1159553
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	98.1200	0.0002	29.3054	16,493.5996	AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	6.9178	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	14.9589	0.0010	19.4141	70.9645	AID743191
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	25.1189	0.0355	20.9770	89.1251	AID504332
activating transcription factor 6	Homo sapiens (human)	Potency	0.3011	0.1434	27.6121	59.8106	AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	23.9145	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	8.5972	0.0578	21.1097	61.2679	AID1159526; AID1159528
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	15.7143	0.0020	7.5337	39.8107	AID891
D(1A) dopamine receptor	Homo sapiens (human)	Potency	8.8939	0.0224	5.9449	22.3872	AID488982; AID488983
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	15.8489	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	24.4126	0.0003	23.4451	159.6830	AID743065; AID743067
atrial natriuretic peptide receptor 2 precursor	Homo sapiens (human)	Potency	16.4816	0.0066	9.8094	18.4927	AID1347050
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	9.9506	0.0037	8.6189	23.2809	AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	29.4076	0.0006	27.2152	1,122.0200	AID651741; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	10.6910	0.4256	12.0591	28.1838	AID504536
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	40.5334	0.0056	12.3677	36.1254	AID624032
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	0.6774	0.0010	6.0009	35.4813	AID943; AID944
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.7943	0.8913	12.0676	28.1838	AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	7.9433	0.3162	12.7657	31.6228	AID881
Cellular tumor antigen p53	Homo sapiens (human)	Potency	13.3332	0.0023	19.5956	74.0614	AID651631
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	7.9433	0.0063	8.2350	39.8107	AID881
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	5.2119	0.0037	8.1081	23.2809	AID2667
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	31.6228	0.0096	10.5250	35.4813	AID1479145
Ataxin-2	Homo sapiens (human)	Potency	28.1838	0.0119	12.2221	68.7989	AID588378
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	37.9330	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	0.6000	0.4000	3.1000	9.7000	AID692192
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	20.6833	0.2100	5.5537	10.0000	AID1442001; AID386625; AID692194
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1C	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	8.3000	0.0220	1.6422	8.9000	AID1207188
Sodium-dependent noradrenaline transporter	Mus musculus (house mouse)	Ki	0.0140	0.0120	0.0905	0.2900	AID134216; AID145696
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	IC50 (µMol)	8.3000	0.0003	2.6311	9.0000	AID1207188
Solute carrier family 22 member 3	Homo sapiens (human)	Ki	42.0000	0.1200	0.1200	0.1200	AID681584
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Prostaglandin G/H synthase 1	Ovis aries (sheep)	Ki	0.1600	0.0016	2.1212	9.0000	AID5444
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	3.7300	0.0001	0.5326	10.0000	AID1801081
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0004	0.6298	10.0000	AID6418
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	Ki	0.0230	0.0002	0.6677	10.0000	AID5241
Muscarinic acetylcholine receptor M5	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.3000	0.0005	2.7802	25.1700	AID142503
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.0051	0.0000	2.0151	10.0000	AID1332024
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0000	2.8005	10.0000	AID1210069
D(2) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.4100	0.0000	0.7472	8.0000	AID1054120
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.7260	0.0000	0.6518	10.0000	AID63979
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0004	0.9086	10.0000	AID6418
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	Ki	0.0230	0.0001	0.6017	10.0000	AID5241
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1600	0.0002	1.8742	10.0000	AID36851
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.2200	0.0001	0.9490	10.0000	AID218673
Sphingomyelin phosphodiesterase	Homo sapiens (human)	IC50 (µMol)	5.0000	5.0000	5.3000	5.6000	AID1357284
D	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.0992	0.0003	0.5026	7.7625	AID179927; AID243189
D(3) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0003	0.3907	5.4000	AID179927
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0003	1.3833	8.4000	AID6418
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.3884	0.0003	1.0914	7.7625	AID243189
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	4.9000	0.0000	0.9296	10.0000	AID218807
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.3884	0.0003	1.0914	7.7625	AID243189
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	4.9000	0.0000	0.9708	10.0000	AID218807
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.3884	0.0003	1.0691	7.7625	AID243189
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	4.9000	0.0000	0.9375	10.0000	AID218807
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1600	0.0002	1.2704	10.0000	AID36851
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.2200	0.0000	0.5751	10.0000	AID218673
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	0.0740	0.0008	1.5416	20.0000	AID351894
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	0.0160	0.0003	1.4656	10.0000	AID145895
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.3884	0.0007	0.9774	9.7000	AID243189
D(1B) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0003	0.3563	5.4000	AID179927
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	0.2200	0.0001	0.8801	8.8500	AID1054119
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.1270	0.0000	0.3855	10.0000	AID5355; AID5444
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.1600	0.0001	0.9549	10.0000	AID5945
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0005	1.4835	7.8000	AID6418
5-hydroxytryptamine receptor 1D	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0031	1.7360	7.8000	AID6418
D(4) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0003	0.3871	5.4000	AID179927
5-hydroxytryptamine receptor 1F	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.7962	7.8000	AID6418
5-hydroxytryptamine receptor 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0004	0.6156	10.0000	AID6418
5-hydroxytryptamine receptor 2B	Rattus norvegicus (Norway rat)	Ki	0.0230	0.0002	0.5909	10.0000	AID5241
5-hydroxytryptamine receptor 6	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.5089	4.6000	AID6418
Histamine H1 receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0001	0.0000	0.3227	1.2589	AID87513
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.0074	0.0001	0.8645	8.7096	AID1054118; AID1285675; AID1299180; AID1332024; AID1336374; AID1597295; AID1718178; AID255317; AID346472; AID351887; AID566273; AID729797; AID751835; AID752199; AID773434
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0879	0.0000	0.7048	8.1930	AID1152645; AID1196338; AID1299179; AID1299181; AID1299182; AID1332036; AID1458656; AID1517958; AID1597295; AID1675411; AID204880; AID338160; AID346472; AID431484; AID612016; AID751835
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0003	0.8197	8.4900	AID179927
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	Ki	0.0290	0.0000	0.7056	10.0000	AID1570058; AID1601979
5-hydroxytryptamine receptor 7	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.4282	4.6000	AID6418
Pleiotropic ABC efflux transporter of multiple drugs	Saccharomyces cerevisiae S288C	IC50 (µMol)	22.0000	1.3000	3.3727	9.6000	AID581672
5-hydroxytryptamine receptor 2C	Mus musculus (house mouse)	Ki	0.1600	0.0008	0.5032	2.8420	AID5679
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	3.7300	0.0003	0.3806	10.0000	AID1801081
5-hydroxytryptamine receptor 5A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.3598	4.6000	AID6418
5-hydroxytryptamine receptor 5B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.3598	4.6000	AID6418
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	0.0270	0.0000	0.4436	5.1768	AID1054121
Histamine H1 receptor	Homo sapiens (human)	Ki	0.0100	0.0000	0.5110	10.0000	AID1675412
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.6003	10.0000	AID144767
Sodium channel protein type 1 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0023	2.8296	9.0000	AID1207159
Sodium channel protein type 4 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0001	3.5075	10.0000	AID1207159
5-hydroxytryptamine receptor 3A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0002	1.1351	4.6000	AID6418
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1600	0.0000	1.8194	10.0000	AID36851
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.2200	0.0000	0.9650	10.0000	AID218673
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	1.9000	0.0040	2.1555	7.2000	AID87880
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	3.7300	0.0002	0.5229	10.0000	AID1801081
5-hydroxytryptamine receptor 7	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	17.1000	2.0300	5.5313	9.9000	AID386625
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0120	2.5312	9.4700	AID1210069
D(2) dopamine receptor	Mus musculus (house mouse)	Ki	0.7260	0.1120	1.6064	3.9811	AID61054
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0001	0.5494	8.4000	AID179927
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.6306	10.0000	AID144767
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0006	1.5257	10.0000	AID144767
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.7472	10.0000	AID144767
Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)	IC50 (µMol)	22.0000	0.0400	4.1137	10.0000	AID1850268
Sodium channel protein type 7 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0360	3.7335	9.0000	AID1207159
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	IC50 (µMol)	8.3000	0.0003	2.5955	9.0000	AID1207188
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	25.6000	0.0007	1.8419	46.0000	AID351888
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	3.3913	0.0009	1.9014	10.0000	AID1207218; AID161281; AID243151; AID243189; AID408340; AID420668; AID51930; AID576612
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	IC50 (µMol)	8.3000	0.0003	2.6311	9.0000	AID1207188
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	8.3000	0.0003	2.2545	9.6000	AID1207188
Sodium channel protein type 5 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0003	3.6484	9.2000	AID1207159
Sodium channel protein type 9 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0060	2.7749	9.0000	AID1207159
Sigma intracellular receptor 2	Rattus norvegicus (Norway rat)	Ki	2.1070	0.0024	1.1050	9.3000	AID1718151
Sodium-dependent serotonin transporter	Mus musculus (house mouse)	Ki	0.0235	0.0004	0.5957	4.1000	AID134217; AID204217
Sodium-dependent dopamine transporter	Mus musculus (house mouse)	Ki	10.0000	0.4040	0.6873	1.0350	AID134215
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.7411	10.0000	AID144767
5-hydroxytryptamine receptor 4	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0050	1.3552	4.6000	AID6418
Solute carrier family 22 member 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	16.0000	0.1800	3.6857	8.8000	AID681348
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1600	3.9571	8.6000	AID692196
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.7411	10.0000	AID144767
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0100	2.7656	10.0000	AID692195
Sodium channel protein type 2 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0000	3.7401	10.0000	AID1207159
5-hydroxytryptamine receptor 3B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0440	0.0004	1.1742	4.6000	AID6418
Sodium channel protein type 3 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0053	2.8085	9.0000	AID1207159
Sigma non-opioid intracellular receptor 1	Rattus norvegicus (Norway rat)	Ki	0.3430	0.0003	0.2671	5.0700	AID1718165
Solute carrier family 22 member 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	9.9000	1.0000	4.4467	10.0000	AID681345
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	IC50 (µMol)	14.0000	0.0007	1.7411	10.0000	AID144767
Sodium channel protein type 11 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0300	4.3695	9.0000	AID1207159
Sodium channel protein type 8 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0011	3.4705	9.0000	AID1207159
Transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8100	0.0008	1.9562	8.8000	AID179927
Transporter	Rattus norvegicus (Norway rat)	Ki	0.0160	0.0001	0.8667	10.0000	AID145696
Sodium channel protein type 10 subunit alpha	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0080	3.1752	9.0000	AID1207159
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Major prion protein	Homo sapiens (human)	EC50 (µMol)	10.0000	0.3000	4.9000	10.0000	AID161627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Snq2p	Saccharomyces cerevisiae EC1118	INH	198.0000	3.2000	6.2600	8.8000	AID581808
Cytochrome P450 1A2	Homo sapiens (human)	Km	5.0000	5.0000	7.0000	9.0000	AID1209253
Cytochrome P450 3A4	Homo sapiens (human)	Km	5.0000	1.9300	5.9060	8.7000	AID1209243
UDP-glucuronosyltransferase 1A4	Homo sapiens (human)	Km	310.0000	7.0000	7.0000	7.0000	AID214939; AID624633
Cytochrome P450 2C19	Homo sapiens (human)	Km	5.0000	1.7000	5.3833	8.7500	AID1209252
Pleiotropic ABC efflux transporter of multiple drugs	Saccharomyces cerevisiae S288C	INH	166.0000	4.2000	6.1833	8.3000	AID581806
UDP-glucuronosyltransferase 1A3	Homo sapiens (human)	Km	472.0000	7.3400	7.3400	7.3400	AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to copper ion	Major prion protein	Homo sapiens (human)
negative regulation of protein phosphorylation	Major prion protein	Homo sapiens (human)
intracellular copper ion homeostasis	Major prion protein	Homo sapiens (human)
response to oxidative stress	Major prion protein	Homo sapiens (human)
learning or memory	Major prion protein	Homo sapiens (human)
long-term memory	Major prion protein	Homo sapiens (human)
negative regulation of protein processing	Major prion protein	Homo sapiens (human)
protein destabilization	Major prion protein	Homo sapiens (human)
negative regulation of type II interferon production	Major prion protein	Homo sapiens (human)
negative regulation of interleukin-17 production	Major prion protein	Homo sapiens (human)
negative regulation of interleukin-2 production	Major prion protein	Homo sapiens (human)
negative regulation of apoptotic process	Major prion protein	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Major prion protein	Homo sapiens (human)
positive regulation of neuron apoptotic process	Major prion protein	Homo sapiens (human)
negative regulation of activated T cell proliferation	Major prion protein	Homo sapiens (human)
response to cadmium ion	Major prion protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Major prion protein	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Major prion protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Major prion protein	Homo sapiens (human)
negative regulation of T cell receptor signaling pathway	Major prion protein	Homo sapiens (human)
protein homooligomerization	Major prion protein	Homo sapiens (human)
regulation of cell cycle	Major prion protein	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Major prion protein	Homo sapiens (human)
cellular response to xenobiotic stimulus	Major prion protein	Homo sapiens (human)
positive regulation of protein targeting to membrane	Major prion protein	Homo sapiens (human)
dendritic spine maintenance	Major prion protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Major prion protein	Homo sapiens (human)
regulation of glutamate receptor signaling pathway	Major prion protein	Homo sapiens (human)
positive regulation of glutamate receptor signaling pathway	Major prion protein	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Major prion protein	Homo sapiens (human)
negative regulation of amyloid-beta formation	Major prion protein	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Major prion protein	Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic process	Major prion protein	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Major prion protein	Homo sapiens (human)
response to amyloid-beta	Major prion protein	Homo sapiens (human)
cellular response to amyloid-beta	Major prion protein	Homo sapiens (human)
regulation of calcium ion import across plasma membrane	Major prion protein	Homo sapiens (human)
neuron projection maintenance	Major prion protein	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
type 8 metabotropic glutamate receptor binding	Major prion protein	Homo sapiens (human)
amyloid-beta binding	Major prion protein	Homo sapiens (human)
protease binding	Major prion protein	Homo sapiens (human)
copper ion binding	Major prion protein	Homo sapiens (human)
protein binding	Major prion protein	Homo sapiens (human)
lamin binding	Major prion protein	Homo sapiens (human)
glycosaminoglycan binding	Major prion protein	Homo sapiens (human)
microtubule binding	Major prion protein	Homo sapiens (human)
tubulin binding	Major prion protein	Homo sapiens (human)
aspartic-type endopeptidase inhibitor activity	Major prion protein	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Major prion protein	Homo sapiens (human)
signaling receptor activity	Major prion protein	Homo sapiens (human)
identical protein binding	Major prion protein	Homo sapiens (human)
ATP-dependent protein binding	Major prion protein	Homo sapiens (human)
transmembrane transporter binding	Major prion protein	Homo sapiens (human)
protein-containing complex binding	Major prion protein	Homo sapiens (human)
protein-folding chaperone binding	Major prion protein	Homo sapiens (human)
molecular adaptor activity	Major prion protein	Homo sapiens (human)
molecular function activator activity	Major prion protein	Homo sapiens (human)
molecular condensate scaffold activity	Major prion protein	Homo sapiens (human)
cupric ion binding	Major prion protein	Homo sapiens (human)
cuprous ion binding	Major prion protein	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
sphingomyelin phosphodiesterase activity	Sphingomyelin phosphodiesterase	Homo sapiens (human)
protein binding	Sphingomyelin phosphodiesterase	Homo sapiens (human)
zinc ion binding	Sphingomyelin phosphodiesterase	Homo sapiens (human)
hydrolase activity, acting on glycosyl bonds	Sphingomyelin phosphodiesterase	Homo sapiens (human)
phosphatidylcholine phospholipase C activity	Sphingomyelin phosphodiesterase	Homo sapiens (human)
acid sphingomyelin phosphodiesterase activity	Sphingomyelin phosphodiesterase	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 4 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 4 subunit alpha	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
amyloid-beta binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
calcium ion binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
protein binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
ATP binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
sodium channel activity	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
osmolarity-sensing monoatomic cation channel activity	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
calmodulin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
fibroblast growth factor binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
enzyme binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein kinase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein domain specific binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ankyrin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nitric-oxide synthase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
scaffold protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 9 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 9 subunit alpha	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
calmodulin binding	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 3 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
ATP binding	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
sodium ion binding	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
dendrite	Major prion protein	Homo sapiens (human)
cytoplasm	Major prion protein	Homo sapiens (human)
endoplasmic reticulum	Major prion protein	Homo sapiens (human)
Golgi apparatus	Major prion protein	Homo sapiens (human)
cytosol	Major prion protein	Homo sapiens (human)
plasma membrane	Major prion protein	Homo sapiens (human)
external side of plasma membrane	Major prion protein	Homo sapiens (human)
cell surface	Major prion protein	Homo sapiens (human)
postsynaptic density	Major prion protein	Homo sapiens (human)
inclusion body	Major prion protein	Homo sapiens (human)
extrinsic component of membrane	Major prion protein	Homo sapiens (human)
nuclear membrane	Major prion protein	Homo sapiens (human)
terminal bouton	Major prion protein	Homo sapiens (human)
intracellular membrane-bounded organelle	Major prion protein	Homo sapiens (human)
membrane raft	Major prion protein	Homo sapiens (human)
extracellular exosome	Major prion protein	Homo sapiens (human)
postsynapse	Major prion protein	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
extracellular space	Sphingomyelin phosphodiesterase	Homo sapiens (human)
lysosome	Sphingomyelin phosphodiesterase	Homo sapiens (human)
extracellular space	Sphingomyelin phosphodiesterase	Homo sapiens (human)
lysosome	Sphingomyelin phosphodiesterase	Homo sapiens (human)
endosome	Sphingomyelin phosphodiesterase	Homo sapiens (human)
lipid droplet	Sphingomyelin phosphodiesterase	Homo sapiens (human)
plasma membrane	Sphingomyelin phosphodiesterase	Homo sapiens (human)
endolysosome	Sphingomyelin phosphodiesterase	Homo sapiens (human)
lamellar body	Sphingomyelin phosphodiesterase	Homo sapiens (human)
lysosomal lumen	Sphingomyelin phosphodiesterase	Homo sapiens (human)
extracellular exosome	Sphingomyelin phosphodiesterase	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
nucleoplasm	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
nuclear body	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
node of Ranvier	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
neuronal cell body	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
axon initial segment	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 1 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 4 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 4 subunit alpha	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
synapse	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
neuronal cell body	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
plasma membrane	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
glial cell projection	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 7 subunit alpha	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleolus	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
endoplasmic reticulum	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cell surface	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
lateral plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sarcolemma	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 9 subunit alpha	Homo sapiens (human)
axon	Sodium channel protein type 9 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 9 subunit alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
plasma membrane	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
axon	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
node of Ranvier	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
paranode region of axon	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
presynaptic membrane	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
glutamatergic synapse	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 2 subunit alpha	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
sarcoplasm	Sodium channel protein type 3 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 3 subunit alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
axon	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
neuronal cell body	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
axonal growth cone	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
C-fiber	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
extracellular exosome	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 11 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
cell junction	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
axon	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
cytoplasmic vesicle	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
node of Ranvier	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
axon initial segment	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
presynaptic active zone membrane	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
parallel fiber to Purkinje cell synapse	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
postsynaptic density membrane	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
glutamatergic synapse	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 8 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
axon	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
presynaptic membrane	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
extracellular exosome	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
glutamatergic synapse	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
clathrin complex	Sodium channel protein type 10 subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (919)

Assay ID	Title	Year	Journal	Article
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1224817	Assays to identify small molecules inhibitory for eIF4E expression	2015	Chemistry & biology, Jul-23, Volume: 22, Issue:7	Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID111833	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1211794	Fraction unbound in blood (not specified)	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID349880	Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1147085	Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 10 to 50 mg/kg, ip	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID288190	Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1211297	Drug recovery in plasma (unknown origin)	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID16331	Delta logPoct-cyc	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID90053	Binding affinity towards histamine receptor by inhibiting specific binding of [3H]-mepyramine (3 nM) in vitro to membranes of rat brain without cerebellum	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1570001	Permeability of compound at 100 ug/ml measured after dilution with PBS/EtOH (70:30) at pH 7.4 after 18 hrs by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID221731	Ability to kill 50% of the animals after 24h, when administered perorally	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID142503	Binding affinity towards muscarinic acetylcholine receptor by inhibiting specific binding of [3H]quinuclidinyl benzilate (0.8 nM) in vitro to membranes of rat brain without cerebellum	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant.
AID218673	Binding affinity towards alpha-1 adrenergic receptor	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID134376	Acute toxicity was measured in mice after peroral administration (293-330)	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID23968	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID624610	Specific activity of expressed human recombinant UGT1A7	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID173926	Potentiation of Methamphetamine effect for intracranial self stimulation(SS) in rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID648667	Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID449543	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 30 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID255317	Percent inhibition against 5-hydroxytryptamine transporter at 1 uM nonselective	2005	Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1517867	Permeability of compound by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1212317	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1529186	Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis	2020	Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4	Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID679763	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Imipramine: 100 uM) in MDR1-expressing MDCKII cells	2002	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID5945	Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1918194	Lipophilicity, log D of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1212318	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM up to 10 mins by LC-MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID180113	Inhibition of the 5-HT [14C]5-HT uptake by rat brain slices In vitro	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1334754	Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID112387	The effect on excitement was measured in mice following oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID172614	Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1131106	Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced salivation	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID243189	Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	A two-state homology model of the hERG K+ channel: application to ligand binding.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1436078	Permeability of compound at 100 ug/ml after 18 hrs by PAMPA	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1571404	Intrinsic clearance in rat liver microsomes measured up to 60 mins in presence of NADPH by LC-MS/MS analysis
AID590293	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 30 mg/kg, ip measured for 6 mins by forced swim test	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents.
AID1776036	Metabolic stability in CD1 mouse liver microsomes assessed as half life at 10 uM incubated for 4 hr by LC-MS analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID1144368	Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 100 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID681584	TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells	2000	American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3	Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID1601979	Displacement of [3H]-citalopram from SERT in rat cortex tissue measured after 60 mins by microbeta scintillation counting analysis	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
AID1144418	Toxicity in po dosed Swiss mouse assessed as behavioral changes	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1625123	Permeability of the compound in pH 7.4 PBS at 200 uL after 18 hrs by PAMPA-BBB assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID114386	Analgesic activity for the inhibition of phenylquinone induced writhing (PQW) after subcutaneous administration to mice	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID28926	Effective permeability corrected for ionization	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1196338	Displacement of [3H]imipramine from human SERT expressed in CHO cells	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID23972	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1720746	Metabolic stability in mouse microsome assessed as intrinsic clearance
AID1172092	Effect on spontaneous locomotor activity in ip dosed mouse during 2 to 6 mins	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
AID1054435	Antidepression-like activity in rat assessed as decrease in immobility time at 60 mg/kg, po by forced swimming test	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.
AID125386	Effective dose (p.o.) required to inhibit monoamine oxidase, in vivo	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1123530	Neuroleptic activity in po dosed mouse assessed as inhibition of d-amphetamine sulfate-induced lethality administered for 0.5 hrs followed by d-amphetamine sulfate challenge measured after 24 hrs	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID603953	In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID449475	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 6 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1144419	Toxicity in po dosed Swiss mouse assessed as clonic convulsion	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID203916	Binding affinity towards serotonin S1 receptor at 1.0 uM	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID113644	Effect on the antagonism of nicotine-induced death (D)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1212333	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of diclofenac	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID729812	Induction of apoptosis in human HeLa cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID147591	Compound was tested for its inhibitory activity against Noradrenaline receptor	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID449542	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 6 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID172474	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID681985	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2A-expressing HEK293 cells	2002	Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID1442001	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID28234	% absorbed in human GI-tract	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID773434	Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1357284	Inhibition of mmLDL-stimulated acid sphingomyelinase in human PBMC lysates using 3H-sphingomyelin as substrate preincubated for 30 mins followed by mmLDL stimulation measured after 2 hrs by HPLC method	2018	European journal of medicinal chemistry, Jun-10, Volume: 153	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1357285	Dissociation constant, pKa of the compound	2018	European journal of medicinal chemistry, Jun-10, Volume: 153	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1161578	Permeability of the compound by PAMPA-BBB assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID1336731	Permeability of compound at 100 ug/ml after 18 hrs by PAMPA	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID113650	Effect on the antagonism of pentylenetetrazole-induced clonic convulsions (P)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1211295	Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID112624	Compound was tested for antidepressant activity by determining the decreased exploratory activity in mice upon oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1847247	Antiviral activity against Ebola virus VLP infected in human HeLa cells assessed as reduction in viral infection preincubated for 1 hr followed by substrate addition and measured after 2 hrs by envision plate reader method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID271644	Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
AID1557178	Permeability of the compound at 100 ug/ml measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1299182	Inhibition of human SERT I172M mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID624617	Specific activity of expressed human recombinant UGT2B17	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1211792	Hepatic clearance in human	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1255974	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID780294	Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 30 to 45 mins	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID598094	Plasma concentration in mouse at 20 mg/kg, ip after 30 mins	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID515780	Intrinsic solubility of the compound in water	2010	Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19	QSAR-based solubility model for drug-like compounds.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID643383	Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID132963	Effect on tetrabenazine-induced suppression of locomotor activity in the mouse after peroral administration	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID1636423	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 21.3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1496040	Effective permeability of the compound in PBS/EtOH at 50 ug/mL after 18 hrs by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID142220	Binding affinity against Muscarinic acetylcholine receptor was determined in homogenized rat cortex tissue using [3H]N-methylscopolamine as radioligand	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues.
AID111827	Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID581807	Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID676720	Antidepressant activity in CF1 mouse assessed as reduction in immobility at 20 mg/kg, po measured after 60 mins by forced-swimming test	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Acylphloroglucinols from Elaphoglossum crassipes: antidepressant-like activity of crassipin A.
AID22538	Half life period is estimated	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1212316	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1720745	Metabolic stability in mouse microsome assessed as half life
AID1436079	Permeability of compound at 25 ug/ml after 18 hrs by PAMPA	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID161281	Inhibition of human Potassium channel HERG expressed in mammalian cells	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID408340	Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Support vector machines classification of hERG liabilities based on atom types.
AID1529182	Protein binding in plasma (unknown origin)	2020	Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4	Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID211846	Acute toxicity (p.o.) after 24 hr was determined in mouse	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID184683	Minimal effective dose in an rat anti-immobility effect using behavioral despair test	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID135326	BBB penetration classification	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID294618	Antidepressant-like activity in Swiss Albino mouse at 10 mg/kg by forced swimming test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID184476	Estimated oral dose depressing motor activity by 50% in rats(po)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID1183278	Permeability of the compound by PAMPA	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID329204	Inhibition of L-[3H]Leu uptake at Aquifex aeolicus sodium-coupled leucine transporter	2007	Nature, Aug-23, Volume: 448, Issue:7156	Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID624616	Specific activity of expressed human recombinant UGT2B15	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1150606	Antidepressant activity in ip dosed rat assessed as prevention of tetrabenazine-induced ptosis	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1332024	Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID134408	Compound was evaluated for 50% lethal dose in mice; LD50 range 100-300 mg/kg	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1212332	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of propranolol	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID183628	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID134602	Lethal dose in mouse p.o.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID309520	Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg administered 30 mins before the test by forced-swimming test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID172611	Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID114157	Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1211296	Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID288187	Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID180129	Inhibition of uptake of 5-HT in rat brain slices	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1211793	Lipophilicity, log P of the compound	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1144378	Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 10 mg/kg, po relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150604	Acute toxicity in ip dosed albino mouse assessed as mortality measured for 5 days	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID1517958	Displacement of [3H]-imipramine from human serotonin transporter expressed in HEK293 cells membranes incubated for 30 mins by microbeta scintillation counting analysis
AID1209243	Drug metabolism in assessed as human CYP3A4-mediated metabolism	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID692184	Therapeutic index, ratio of Cmax in human to IC50 for human MATE2-K	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID180130	Inhibition of uptake of Dopamine in rat brain slices	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1209247	Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by multiple depletion curves method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1713987	Effective permeability of the compound at 25 ug/ml after 18 hrs by UV plate reader based PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID64630	Binding affinity towards dopamine receptor D2 at 1.0 uM concentration	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID692193	Inhibition of human OCT2 A270S mutant expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID179941	Inhibition of Norepinephrine uptake from rat diencephalon-midbrain	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID235625	Therapeutic index administered intraperitoneally in mouse	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1890389	Metabolic stability in human liver microsomes assessed as intrinsic clearance	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID1091956	Apparent hydrophobicity, log D of the compound in Octanol-buffer	2011	Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7	Importance of physicochemical properties for the design of new pesticides.
AID26300	log P values determined at pH 7.4	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID692189	Therapeutic index, ratio of Cmax in human to IC50 for human OCT2 A270S mutant	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID1545656	Half-life in CD1 mouse liver microsomes by HPLC analysis	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID118917	Compound was tested for lethality in mice at a dose 80 mg/kg intraperitoneally; L denotes lethal at this dose	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID692194	Inhibition of human OCT1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID330659	Effect on life span of Caenorhabditis elegans at 50 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID540237	Phospholipidosis-positive literature compound observed in rat
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID172608	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID179383	Concentration of compound to inhibit 50% of [3H]norepinephrine neurotransmitter uptake in rat brain	1980	Journal of medicinal chemistry, Aug, Volume: 23, Issue:8	Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID196059	Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID180366	The compound was tested for antidepressant activity by its ability to inhibit muricidal intraperitoneally	1980	Journal of medicinal chemistry, Mar, Volume: 23, Issue:3	Central nervous system activity of 7-substituted 1-azaphenoxathiin analogues and their oxidation products.
AID1597295	Displacement of [3H] imipramine from human recombinant 5-HT transporter measured after 60 mins by scintillation counter method
AID1211795	Dissociation constant, pKa of the compound	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID117217	Lethal dose was evaluated against reserpine induced hypothermia in mice by intraperitoneal administration	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID23708	Partition coefficient (logP)	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID26296	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1625122	Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID129179	Antidepressant activity was determined to prevent tetrabenazine-induced ptosis(TBZ) after oral administration in mice	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID235738	Therapeutic index as the ratio of LD50 to that of ED50 values.	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID1285675	Displacement of [3H]imipramine from human recombinant 5-HT transporter expressed in CHO cells	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID29812	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID118797	Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID235626	Therapeutic index administered perorally in mouse	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID114395	Tested for antagonism of oxotremorine hypothermia (OX) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID476994	Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 6 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID476995	Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID293491	Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg, ip thrice a day by 5-mins swim test	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID196031	Inhibition of [3H]norepinephrine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.01-0.07	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1375645	Antiviral activity against Ebolavirus like particle harboring EBOV VP40 assessed as inhibition of viral infection in human HeLa cells preincubated with host cells for 1 hrs followed by viral inoculation by beta-lactamse reporter assay	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID196028	Inhibition of [3H]dopamine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.09-0.18	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID427197	Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1209252	Drug metabolism in assessed as human CYP2C19-mediated metabolism	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID294622	Antidepressant-like activity in C57BL/6J mouse at 10 mg/kg by tail suspension test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID1514461	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 60 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID288186	Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID113415	Compound was tested for total number of explored holes in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID134217	Tested in vitro for serotonin(5-HT) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID112388	Effect on pupil dilation was measured in mice upon oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1131083	Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 5. Conformationally mobile analogues derived by furan ring opening.
AID1123529	Neuroleptic activity in po dosed rat assessed as concentration required to cause 50% reduction of motor activity	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID1144416	Antispasmodic activity in guinea pig ileum assessed as inhibition of histamine-induced spasm	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1132844	Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing response at 30 mg/kg, po administered 30 mins prior to acetic acid-challenge relative to control	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID1223490	Apparent permeability across human differentiated Caco2 cells	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1363637	Metabolic stability in mouse liver microsomes assessed as compound remaining at 25 uM after 1 hr in presence of NADPH by LC-MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1144413	Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced ptosis administered 1 hr prior to reserpine challenge	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID110188	Antagonism of tetrabenazine (TBZ)-induced depression in mice measured for ptosis	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID222712	Effect on recovery time for coma induced in mice by cerebral concussion (treated group)	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1172091	Antidepressant-like activity in mouse assessed as reduction in immobility time at 10 to 20 mg/kg, ip dosed 60 mins before test by forced swim test	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
AID134948	Mouse behavior activity was determined; S-D=Stimulant-Depressant	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID288901	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 30 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID338160	Displacement of [3H]citalopram from serotonin transporter	1993	Journal of natural products, Apr, Volume: 56, Issue:4	The role of receptor binding in drug discovery.
AID161627	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	2003	Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17	Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID178315	Antidepressant activity was determined for potentiation of head twitching induced by 5-hydroxytryptophan-(5-HTP) after intraperitoneal administration in pargyline-pretreated rats	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID112136	Effective dose required to potentiate yohimbine hydrochloride induced lethality in mice, administered intraperitoneally	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1195628	Antidepressant-like activity in mouse assessed as decrease in immobility time at 10 mg/kg, po by forced swimming test	2015	Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10	Pyridinic analog of the natural product (-)-spectaline as potential adjuvant for the treatment of central nervous system disorders.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID6418	Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID225162	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for single administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1752934	Intrinsic clearance in mouse liver microsomes measured upto 40 mins by LC-MS/MS analysis
AID19419	Partition coefficient (logD7.4)	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID431484	Inhibition of [3H]serotonin reuptake at serotonin transporter	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1517957	Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in CHO-K1 cell membranes incubated for 60 mins by microbeta scintillation counting analysis
AID134601	Lethal dose in mouse i.p.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1458670	Toxicity in CD-1 mouse assessed as effect on spontaneous locomotory activity by measuring number of areas crossed administered for 30 mins measured every 1 min for first 5 mins	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID196063	Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID624606	Specific activity of expressed human recombinant UGT1A1	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1319973	Permeability of the compound by PAMPA assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID129955	Antidepressant activity measured by effects on tetrabenzidine (TBZ) inhibited exploratory activity.	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID729820	Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1818858	Antidepressant activity in Wistar rat model of scopolamine-induced depressive like behavior assessed as increased swimming time at 1 mg/kg measured after 24 hrs by forced swimming test	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats.
AID692183	Protein binding in human plasma	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID780297	Effect on isolation-stressor in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 5 to 60 mins	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID288894	Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg, ip administered 30 mins before the test in forced-swimming test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID114920	Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 25 mg/kg	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4	New dibenzothiadiazepine derivatives with antidepressant activities.
AID310931	Partition coefficient, log P of the compound	2007	Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID392739	Antidepressant activity against Swiss-Webster mouse assessed as reduction in duration of immobility at 10 mg/kg, ip after 1 hr by tail suspension behavioral despair test relative to control	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain.
AID123344	Percentage of total immobility time after an intraperitoneal dose of 1.5 (mg/kg) in porsolt's test	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID1071344	Permeability of the compound by BBB-PAMPA	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID185200	Time-related potentiation of methamphetamine-induced anorexia in rats at the lowest active dose.	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1334753	Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1211294	Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID178370	Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in rat	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID181669	In vitro inhibition of norepinephrine uptake in rat brain synaptosomes using [3H]NE	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID1352675	Effective permeability at 25 ug/ml after 18 hrs by PAMPA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1255970	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID132108	In vivo effect on Tetrabenazine ptosis activity in mice following i.p. administration.	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID183627	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID624609	Specific activity of expressed human recombinant UGT1A6	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID692185	Cmax in human	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID119457	Dose required to reduce reserpine induced hypothermia was measured after sc administration of reserpine at 2.5 mg/kg, 18 hr before the rectal-temperature recording in mice	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4	New dibenzothiadiazepine derivatives with antidepressant activities.
AID1264447	Permeability of the compound by PAMPA method	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID214939	Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID127795	In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Tetracyclic pyridazines as potential psychopharmacological agents.
AID309530	Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 20 mg/kg administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID692196	Inhibition of human MATE2-K expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID476996	Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID678719	Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID119219	Rotation number in mice was determined at 9 minutes after a dose of 10 mg/Kg	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID114407	Anticonvulsant activity to prevent pentamethylenetetrazole (MTZ) induced lethality in mice after oral administration	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID222068	Effect on the sleeping time of mice anesthetized with halothane (treated group);NT means not tested	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID351894	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID180151	Inhibitory activity against uptake of [3H]norepinephrine into rat brain synaptosomes.	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID1123532	Antidepressant activity in po dosed mouse assessed as inhibition of tetrabenazine hexamate-induced depression administered 1 hr followed by tetrabenazine hexamate challenge measured after 30 mins	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID1570058	Displacement of [3H]-citalopram from SERT in rat cortex tissue incubated for 60 mins by microbeta scintillation counting method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
AID496020	Plasma protein binding in human after 30 min by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1144417	Acute toxicity in po dosed Swiss mouse assessed as mortality after 7 days	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID130125	Compound was evaluated for maximal electroshock antagonism (MES) against mice	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID361986	Lipophilicity, log D of compound at pH 7.4 by shake flask method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID113875	Intraperitoneal dose required for antagonism of d-amphetamine lethality in grouped mice (GAL).; inact means compound is inactive at 20 mg/kg dose.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID114488	Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 2 hr after i.p. administration.	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols.
AID1458668	Toxicity in Swiss albino mouse assessed as effect on spontaneous locomotory activity measuring number of areas crossed administered for 30 mins measured every 2 mins up to 6 mins	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID184473	Reduction in motor activity in rats following p.o. administration.	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID478691	Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 150.3 +/- 11.1 sec)	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID681986	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2-expressing HEK293 cells	2002	Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID127858	Evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID113655	Effect on the potentiation of gamma-butyrolactone-induced sleep (gamma-B)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID351887	Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID624608	Specific activity of expressed human recombinant UGT1A4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1211293	Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1514445	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 15 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID449471	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 20 mg/kg, ip administered 30 mins before test by forced swimming test	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID181621	Antimuricide effect was observed in the olfactory bulb removed rats; antimuricide effect at 30 mg/kg; + = 31 - 50%	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID1739433	Metabolic stability in human liver microsomes assessed as half life at 100 uM measured upto 30 mins	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID179763	In vitro inhibitory activity against [3H]5-HT uptake into crude synaptosomes from whole rat brain.	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID1192730	Permeability of the compound by PAMPA	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID294621	Antidepressant-like activity in C57BL/6J mouse at 5 mg/kg by tail suspension test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID28921	Partition coefficient (logP) (hexadecane)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID5444	Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID476989	Antidepressant-like activity in Swiss mouse assessed as immobilization time at 20 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID112385	The effect on electroshock protection in mice following oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID427196	Membrane permeability by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID611034	Antidepressant activity in Swiss mouse assessed as reduction of immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 0 %)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID114393	Tested for antagonism of nicotine-induced death (D) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1382495	Half life in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1285689	Half life in mouse liver microsomes at 20 uM preincubated for 15 mins followed by addition of NADPH-regenerating system measured after 5 to 90 mins by UPLC/MC analysis	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207660	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID624633	Drug glucuronidation reaction catalyzed by human recombinant UGT1A4	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1470712	Anti-depressant like activity in Swiss albino mouse assessed as reduction in immobility time at 60 mg/kg, po administered 60 mins prior to test measured for 5 mins by forced swim test relative to control	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID204217	Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1144379	Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 20 mg/kg, po relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID288192	Partition coefficient, log P of the compound	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID751835	Binding affinity to human 5-HT transporter by radioligand displacement assay	2013	European journal of medicinal chemistry, May, Volume: 63	Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID1777550	Displacement of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K(Biotin) from Europium chelated human BRD4 bromodomain 2 (342 to 460 residues) measured after 2 hrs by TR-FRET assay	2021	Bioorganic & medicinal chemistry, 09-01, Volume: 45	Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
AID1384014	Effective permeability of the compound dissolved in PBS at 100 uM after 3 to 6 hrs by PAMPA	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID373867	Hepatic clearance in human hepatocytes in absence of fetal calf serum	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID5679	Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID114565	Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1382494	Intrinsic clearance in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1823847	Anti-antidepressant like activity in Wistar rat assessed as reduction in locomotor activity by measuring total immobility time by Forced swim test
AID1514446	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID493410	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility duration at 30 mg/kg, ip administered 3 times for 24 hrs measured after 1 hr last post dose by tail suspension test	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Synthesis, antidepressant evaluation and QSAR studies of novel 2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-N-(substituted phenyl)acetamides.
AID1718151	Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID624632	Drug glucuronidation reaction catalyzed by human recombinant UGT1A3	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1212329	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of dextromethorphan	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID288897	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 10 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID222711	Effect on recovery time for coma induced in mice by cerebral concussion (control group)	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1585850	Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID114396	Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID729814	Induction of apoptosis in human MUTU-I cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID28923	Effective permeability measured with Caco-2 cells	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID288893	Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg, ip administered 30 mins before the test in forced-swimming test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID145696	Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID114738	Delay in response to noxious heat stimuli in mice by tail flick method after subcutaneous administration	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1353530	Antidepressant like activity in Swiss albino mouse assessed as immobility time at 10 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID132665	In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID181670	In vitro inhibition of 5-HT uptake in rat brain synaptosomes using [3H]- 5-hydroxytryptamine	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID1091957	Apparent permeability of the compound by PAMPA	2011	Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7	Importance of physicochemical properties for the design of new pesticides.
AID624618	Specific activity of expressed human recombinant UGT2B4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1144367	Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 25 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID223128	Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID114043	Muscle relaxant effect was measured as ED50 which is the dose that causes muscle relaxation in 50% of the mice, po	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID183074	Inhibition of GABA uptake from rat diencephalon-midbrain at 100 uM concentration	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID1465314	Effective permeability of the compound by PAMPA	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID681116	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells	2002	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1480942	Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1514463	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 120 mins by LC-MS/MS analysis (Rvb = 100%)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID680295	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Imipramine: 20 uM) in MDR1-expressing NIH-3T3 cells	2004	Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4	Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1212319	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM measured at 10 mins by LC-MS analysis in presence of ammonium chloride	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1703748	Intrinsic clearance in human liver microsomes at 0.1 uM in presence of NADPH measured upto 60 mins by LC/MS/MS analysis	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID1557184	Permeability of the compound at 25 ug/ml by PAMPA-BBB assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID692186	Therapeutic index, ratio of Cmax in human to IC50 for human OCT1	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID87513	Compound tested for its inhibitory activity against Histamine H1 receptor	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID48901	Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 2 mg/Kg	2001	Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22	A new class of antiarrhythmic-defibrillatory agents.
AID180114	Inhibition of the NE [3H]Norepinephrine uptake by rat brain slices In vitro	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1568822	Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID223123	Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID112642	Antidepressant activity by determining the reversal of tetrabenazine-induced ptosis upon oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID178876	Compound was tested for the inhibition of tetrabenazine-induced sedation in rat, after peroral administration	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID692187	Therapeutic index, ratio of Cmax in human to IC50 for human MATE1	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID288194	Intrinsic artificial membrane permeability coefficient, log P0 of the compound	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1427527	Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID218807	Binding affinity towards alpha-2 adrenergic receptor	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID590299	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility duration at 30 mg/kg, ip administered 30 mins prior to test measured after 30 mins by tail suspension test (Rvb = 79.9%)	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents.
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID23960	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID449476	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 30 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID180132	Inhibition of uptake of tritiated norepinephrine (NE) into rat brain synaptosomes	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID1390040	Effective permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1517838	Permeability of the compound in pH 7.4 PBS/EtOH at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1212314	Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1132845	Analgesic activity in mouse by hot-plate test	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID112984	Compound was tested for the inhibition of tetrabenazine-induced sedation in mice, after peroral administration	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1357283	Inhibition of TNFalpha-stimulated apoptosis in human PBMC assessed as apoptotic cells at 2 uM preincubated for 30 mins followed by TNFalpha stimulation measured after 4 hrs by YO-PRO-1/Hoechst 33342 staining based assay relative to control	2018	European journal of medicinal chemistry, Jun-10, Volume: 153	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID449474	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 30 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID132117	Tested in vivo for head twitches antagonizing activity in mice	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID288902	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID5355	Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID107473	Compound was tested for total number of falls in 100 seconds after intraperitoneal administration of 37.5 mg/Kg in mice by rotarod test	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID288907	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 30 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID22345	Therapeutic plasma levels for the compound was evaluated.	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID63979	Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1150605	Antidepressant activity in ip dosed mouse assessed as prevention of reserpine-induced ptosis	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID131890	Effective dose required to antagonise clonidine-induced antinociception(ACA) in mouse by peroral administration; NT is Not Tested	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1545657	Intrinsic clearance in CD1 mouse liver microsomes by HPLC analysis	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID1374214	Effective permeability of the compound in pH 7.4 buffer after 18 hrs by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID91721	Inhibition of binding of [3H]imipramine to imipramine receptor in rat brain	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID112987	Compound was tested for the neuroleptic activity as measured by it's antagonism of d-amphetamine induced lethality in grouped mice(GAL) when administered perorally	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID112381	The effect on 24-hour mortality in mice following oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID118792	Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 40 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID131526	Effective dose against tetrabenazine induced ptosis in mice administered orally	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID29423	HPLC capacity factor (k')	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1713986	Effective permeability of the compound in PBS/ethanol buffer (9:1) at 25 ug/ml after 10 hrs by UV plate reader based PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID180468	In vitro inhibitory activity against [3H]-5-HT uptake into crude synaptosomes from whole rat brain.	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID351888	Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID343685	Ratio of drug level in brain to blood in Wistar rat	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Toward prediction of alkane/water partition coefficients.
AID133113	Prevention of reserpine-induced ptosis in the mouse after peroral administration	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID433879	Antidepressant activity in Swiss-Webster mouse assessed as reduction in duration of immobility time at 10 mg/kg, ip by tail suspension behavioral despair test	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities.
AID1675412	Binding affinity to H1 receptor (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.
AID1264455	Permeability of the compound by high throughput PAMPA method	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID183626	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID420669	Lipophilicity, log D at pH 7.0	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID23962	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1752938	Half life in mouse liver microsomes measured upto 40 mins by LC-MS/MS analysis
AID729821	Reduction in cell viability of human MUTU-I cells after 24 hrs by Alamar blue viability assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID179990	Tested in vivo for serotonin syndrome antagonizing activity in rat	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID360444	Displacement of [3H]RTI82 from DAT in rat striatal membrane	2007	The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12	Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.
AID130699	In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID1458675	Inhibition of SERT expressed in rat brain synaptosomes assessed as decrease in incorporation of [3H]serotonin measured after 15 mins by scintillation counting method	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1750323	Half life in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID184234	Maximum inhibition of immobility in the rat (Expressed as percentage of immobility observed in vehicle controls)	1999	Journal of medicinal chemistry, May-06, Volume: 42, Issue:9	Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
AID129177	Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in untreated mice after ip administration	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1384013	Effective permeability of the compound dissolved in PBS containing 1% F-127 at 100 uM after 3 to 6 hrs by PAMPA	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID1374552	Antidepressant-like activity in Wistar rat assessed as decrease in immobility time at 30 mg/kg, ip administered 30 mins prior to test measured for 5 mins by forced swim test	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID449473	Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 6 mins	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1437174	Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID180133	Inhibition of uptake of tritiated serotonin (5-HT) into rat brain synaptosomes	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID60003	Inhibition of the response to phenethylamine was measured	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID681443	TP_TRANSPORTER: inhibition of TEA uptake by Imipramine at 1mM in Octn1-HRPE cells	2000	Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2	Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID288184	Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1336374	Displacement of [3H]imipramine from human recombinant 5HT transporter expressed in CHO cells measured after 60 mins by scintillation counting method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID1192731	Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID1132846	Antidepressant activity in mouse assessed as reversal of reserpine-induced hypothermia measured as cumulative temperature rise at 30 mg/kg administered 17 hrs post reserpine-challenge	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID225164	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for repeated administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1223488	1-Octanol-water distribution coefficient, log D of the compound at pH 7.4	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID26515	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID129450	Anti-tetrabenazine (TBZ) activity, ability to prevent TBZ-induced ptosis in mice	1984	Journal of medicinal chemistry, Sep, Volume: 27, Issue:9	Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID48900	Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 1 mg/Kg	2001	Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22	A new class of antiarrhythmic-defibrillatory agents.
AID1458656	Displacement of [3H]-imipramine from human serotonin transporter expressed in HEK-293 cell membranes after 30 mins by scintillation counting	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID112481	Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration.; value ranges from 2.2-2.4	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID114561	Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1212335	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of atorvastatin	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1375641	Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells at pH 5.2 by SYPRO orange dye-b	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID394126	Antidepressive activity in Albino Swiss mouse assessed as total immobility time at 15 mg/kg, ip after 30 mins measured for 4 mins by forced swimming test	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes.
AID222978	Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID204880	Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1728286	Metabolic stability in mouse liver microsomes assessed as parent compound remaining measured after 90 mins in presence of NADPH	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Novel σ
AID624613	Specific activity of expressed human recombinant UGT1A10	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1496041	Effective permeability of the compound by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID114394	Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID294617	Antidepressant-like activity in Swiss Albino mouse at 5 mg/kg by forced swimming test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID28925	Highest effective permeability across hexadecane membrane (pH 4-8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1352674	Effective permeability at 25 ug/ml after 16 hrs by PAMPA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1863562	Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1211791	Fraction unbound in human hepatocytes	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID179154	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID330661	Effect on life span of Caenorhabditis elegans at 200 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID598090	Antidepressant-like activity in mouse assessed as immobility time at 20 mg/kg, ip after 30 mins by forced swim test	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID681345	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT2-expressing MDCK cells	2001	Pharmaceutical research, Nov, Volume: 18, Issue:11	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID293501	Effect on motor co-ordination in Swiss mouse assessed as number of falls at 15 mg/kg, ip after 10 days by Rota-rod test	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID1175702	Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 0.5 mg/kg, ip measured for 5 mins by tail suspension test relative to control	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1777549	Displacement of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K(Biotin) from Europium chelated human BRD4 bromodomain 1 (49 to 170 residues) measured after 2 hrs by TR-FRET assay	2021	Bioorganic & medicinal chemistry, 09-01, Volume: 45	Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
AID19257	Logarithm of partition coefficient of the neutral form of compound given for chloroform/water solvent system	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID25866	Protonation constant of the compound.	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID111841	Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID729813	Induction of apoptosis in human DG75 cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID581672	Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID478701	Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 138.6 +/- 12 sec)	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1144415	Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced spasm	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1453097	Effective permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA-BBB assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1209251	Drug metabolism in human liver microsomes by optimal design approach	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID123350	Percentage of total immobility time after an intraperitoneal dose of 7.5 (mg/kg) in porsolt's test	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID172615	Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID346472	Displacement of radiolabeled imipramine from human SERT	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1211797	Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID114156	Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1091958	Hydrophobicity, log P of the compound in octanol-water by shaking-flask method	2011	Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7	Importance of physicochemical properties for the design of new pesticides.
AID111839	Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 40.0 mg/kg	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID141547	Concentration of compound for 50% displacement of [3H]QNB from Muscarinic acetylcholine receptor in rat brain	1980	Journal of medicinal chemistry, Aug, Volume: 23, Issue:8	Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1647892	Antidepressant activity in Wistar rat assessed as immobility time at 45 mg/kg, ip measured for 5 mins by forced swim test (Rvb = 271.9 +/- 7.2 sec)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
AID131880	Effective dose required for inhibition of tetrabenazine-induced ptosis in mouse by peroral administration;Values ranges from: 1.8-9.3	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID612016	Displacement of [3H]imipramine from human 5HT transporter	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID1054121	Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID113292	Dose of compound required to reduce apomorphine-induced hypothermia by 50% in mice by hypothermia (Apo 16)test	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4	New dibenzothiadiazepine derivatives with antidepressant activities.
AID131528	Effective dose against tetrabenazine induced ptosis in mice administered subcutaneously	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID130716	In vivo inhibition of uptake of nor epinephrine in mouse heart; value ranges from 3.1-14.6	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID172472	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID118790	Retention for passive avoidance learning in mice at dose 20 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1091955	Dissociation constant, pKa of the compound at pH 7.3	2011	Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7	Importance of physicochemical properties for the design of new pesticides.
AID1568812	Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID118210	Ability to prevent the reserpine induced hypothermia in mice relative to amitriptyline	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID128147	Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Tetracyclic pyridazines as potential psychopharmacological agents.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209248	Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by optimal design approach	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1636268	Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID288193	Flux ionization constant, pKa of the membrane permeability coefficient of the compound	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID729819	Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1299180	Inhibition of human SERT W103A mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID225165	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for single administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID180131	Inhibition of uptake of nor epinephrine in rat brain slices	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID130700	In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID128659	Analgesic activity was determined for inhibition of phenyl-p-quinone-induced writhing (PQW) after subcutaneous administration in mice	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1129361	Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID714926	Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during 6 mins period at 20 mg/kg, po administered 30 mins before test by tail suspension test (Rvb = 185.7 +/- 5.33 secs)	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues.
AID1211798	Intrinsic clearance in human using well stirred liver model by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID123347	Percentage of total immobility time after an intraperitoneal dose of 30 (mg/kg) in porsolt's test	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID1465293	Effective permeability of the compound at 100 ug/ml by PAMPA-BBB assay	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1444094	Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID476988	Antidepressant-like activity in Swiss mouse assessed as immobilization time at 10 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID118793	Retention for passive avoidance learning in mice at dose 5 mg/kg	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Cognition-activating properties of 3-(Aryloxy)pyridines.
AID176472	Potency to produce a significant inhibition of immobility in rat	1999	Journal of medicinal chemistry, May-06, Volume: 42, Issue:9	Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
AID1890429	Metabolic stability in human liver microsomes assessed as half life	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID113656	Effect on the potentiation of yohimbine-induced toxicity (Y) in aggregated mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID307535	Antidepressant effect in mouse at 10 mg/kg, ip assessed as reduction in immobility duration after 30 mins by forced swimming test relative to control	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.
AID1209255	Drug metabolism in assessed as human CYP1A2-mediated intrinsic clearance per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID179153	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID1909448	Permeability of the compound by PAMPA-BBB assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1285690	Intrinsic clearance in mouse liver microsomes at 20 uM preincubated for 15 mins followed by addition of NADPH-regenerating system measured after 5 to 90 mins by UPLC/MC analysiS	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID780292	Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 45 to 60 mins	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID288185	Permeability coefficient through artificial membrane in presence of stirred water layer	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID195890	In vitro inhibition of dopamine (DA) uptake in synaptosomal preparation of rat brain	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1458659	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time administered for 30 mins measured last 4 mins of 6 mins test by forced swimming test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID172613	Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID363880	Neurotoxicity in albino mouse assessed as animal in lateral position at 10 mg/kg, ip administered 1 hr prior to ethanol challenge measured after 30 mins	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1823851	Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID144767	Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID114415	Antipsychotic activity to prevent amphetamine induced lethality in mice after oral administration	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1332035	Ratio of IC50 for human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake to Ki for [3H]citalopram from human SERT expressed in HEK293 cell membranes	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID29925	Volume of distribution in man (IV dose)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1421886	Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1571403	Half life in rat liver microsomes in presence of NADPH by LC-MS/MS analysis
AID1718178	Inhibition of SERT (unknown origin)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1212326	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of nigericin and monensin	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID124991	Writhing number was determined against clonidine induced analgesia by the compound at an intraperitoneal dose of 10 mg/Kg in mice	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1305711	Half life in mouse liver microsomes at 0.1 uM	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID193219	Percentage decrease in immobility time, after acute administration (intraperitoneally) in rat dosed at 20 mg/kg	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity.
AID131702	Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in mouse	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1458667	Anxiolytic-like activity in Swiss albino mouse assessed as suppression of movement administered for 30 mins by four-plate test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1212328	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of astemizole	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID611038	Antidepressant activity in Swiss mouse assessed as immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 166 +/- 12.23 to 218.54 +/- 8.11 Secs)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID1718165	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID386625	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1144366	Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 20 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624615	Specific activity of expressed human recombinant UGT2B10	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID196036	Inhibition of [3H]5-HT uptake into rat brain synaptosomes in vitro;Values ranges from: 0.14-0.22	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1144414	Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced hypothermia measured over 5 hrs	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1212325	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1374215	Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1209246	Drug metabolism in assessed as human CYP2C19-mediated maximum rate of reaction per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID34292	Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179973	Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID436830	Antidepressant-like activity in NMRI mouse assessed as reduction in immobility time at 16 mg/kg, ip by forced swimming test relative to control	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.
AID23973	Partition coefficient (logD, measured by HPLC, log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID172473	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1750324	Intrinsic clearance in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID714927	Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during last 4 mins of single 6 mins test session at 20 mg/kg, po by forced swim test (Rvb = 75.33 +/- 3.35 secs)	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues.
AID1739434	Metabolic stability in human liver microsomes assessed as intrinsic clearance at 100 uM measured per mg protein upto 30 mins	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID114489	Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 4 hr after i.p. administration.	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID196022	In vitro inhibition of norepinephrine (NE) uptake in synaptosomal preparation of rat brain	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID225159	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for single administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID26538	log K was measured potentiometrically in Brij35 medium	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID28679	Partition coefficient (logD6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID112146	Effective dose required to prevent reserpine ptosis in mice, administered intraperitoneally	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID20050	Human absorption A (%)	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1442006	Ratio of Kii for human OCT1-ASP+-inhibitor complex to Kis for human OCT1-inhibitor complex by Lineweaver-Burk plot analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID1375643	Antiviral activity against Ebolavirus like particle harboring full length EBOV Zaire wt/GIN/2014/ Kissidougou-C15 envelope glycoprotein and Influenzae virus envelope assessed as inhibition of viral infection in MDCK-SIAT1 cells after 48 hrs by e-GFP-based	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID113648	Effect on the antagonism of oxotremorine-induced hypothermia (OX)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1832393	Microsomal stability in human liver microsome assessed as half life at 0.1 mg/ml	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID130904	Inhibition of radioactive NE [3H]norepinephrine uptake into mouse heart	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1818860	Antidepressant activity in Wistar rat model of scopolamine-induced depressive like behavior assessed as decrease in immobility time at 1 mg/kg measured after 24 hrs by forced swimming test	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats.
AID61054	Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID225158	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for repeated administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID114392	Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID288898	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID309522	Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID420787	Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID692192	Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID237685	Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID34293	Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1357282	Inhibition of mmLDL-stimulated apoptosis in human PBMC assessed as apoptotic cells at 2 uM preincubated for 30 mins followed by mmLDL stimulation measured after 4 hrs by YO-PRO-1/Hoechst 33342 staining based assay (Rvb = 100%)	2018	European journal of medicinal chemistry, Jun-10, Volume: 153	NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1147092	Antipsychotic activity in Sprague-Dawley rat assessed as prevention of d-amphetamine-induced stereotyped behavior at 32 mg/kg, po measured for 1 min after 90, 100, and 110 mins injection of amphetamine	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID134216	Tested in vitro for norepinephrine (NE) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID103232	Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID1131107	Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced mydriasis	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID205267	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID205268	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID193220	Percentage decrease in immobility time, after subchronic administration (intraperitoneally) in rat dosed at 20 mg/kg	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity.
AID116867	Compound at an intraperitoneal dose of 10 mg/Kg was tested for the inhibition of abdominal constriction in mice	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1901321	Drug uptake in mouse liver microsomes incubated for 90 mins in presence of NAPDH
AID22432	Volume of distribution in the plasma fluid was determined	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1131104	Antidepressant activity against reserpine-induced hypothermia CFLP mouse model assessed as change in esophageal temperature at 20 mg/kg, po treated before 2 to 24 hrs of reserpine challenge	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID581806	Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1212330	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of chloroquine	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1528959	Antidepressant-like activity in Swiss mouse assessed as reduction in immobility time at 30 mg/kg, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail suspension test
AID681348	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT1-expressing MDCK cells	2001	Pharmaceutical research, Nov, Volume: 18, Issue:11	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID1255968	Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID598130	Drug level in mouse brain at 20 mg/kg, ip after 30 mins	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID114327	Antiphysostigmine effect was measured as ED50,po	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID176192	Effective dose to block muricidal behavior in rat when administered ip	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents.
AID1299179	Inhibition of wild-type human SERT expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID420668	Inhibition of human ERG in MCF7 cells	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1292332	Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1319976	Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID363879	Neurotoxicity in albino mouse assessed as animal remained on the revolving rod at 10 mg/kg, ip after 30 mins by rotarod test.	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID598134	Ratio of drug level in brain to plasma in mouse at 20 mg/kg, ip after 30 mins	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID1292330	Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID129961	Antidepressant activity measured by tetrabenazine (TBZ) induced ptosis in mice after intraperitoneal administration	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID145895	Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1131108	Anticholinergic effect in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID729797	Inhibition of human SERT expressed in HEK293-MSR cells by 5-HT uptake assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1212327	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride, nigericin and monensin	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1322339	Antidepressant-like activity in mouse assessed as immobility time at 10 mg/kg, ip by tail suspension test (Rvb = 154.2 +/- 10.2 sec)
AID112383	The effect on ataxia in mice following oral administration	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Imine analogues of tricyclic antidepressants.
AID1144365	Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 10 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID51930	K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1	2002	Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18	Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID113652	Effect of test compound on the potentiation of apomorphine-induced gnawing (AG) in aggregated mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID116717	Acute cytotoxicity was evaluated as LD50 in mice (ip)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID122478	Compound was tested for myorelaxant action (time in seconds on the horizontal wire with forelegs) after intraperitoneal administration of 37.5 mg/Kg in mice by traction test	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID28235	Unbound fraction (plasma)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1702354	Antidepressant-like activity in Wistar rat assessed as minimum effective dose causing reduction in immobility time administered intraperitoneally with compound 60 mins prior to testing and measured for 5 mins test period by Porsolt-forced swim test
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID692195	Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID196062	Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1134043	Antitetrabenazine activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine-induced ptosis challenged with tetrabenazine after 30 mins later and after another 30 mins of drug treatment	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID78164	Concentration required to reducing the histamine induced contraction by 50% was measured	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID1421885	Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID132666	In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID127789	In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Tetracyclic pyridazines as potential psychopharmacological agents.
AID131997	Evaluated for antagonism of reserpine induced hypothermia	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID172609	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1299181	Inhibition of human SERT I179C mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID271645	Antiprion activity in ScN2a cells assessed as complete reduction of protease-resistant scrapie prion protein	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
AID1353531	Antidepressant like activity in Swiss albino mouse assessed as immobility time at 20 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID1519022	Metabolic stability in C57BL/6 mouse liver microsomes assessed as parent compound remaining at 25 uM incubated for 90 mins in presence of NADPH by LC-qTOF/MS analysis
AID179384	Concentration of compound to inhibit 50% of [3H]-5-HT neurotransmitter uptake in rat brain	1980	Journal of medicinal chemistry, Aug, Volume: 23, Issue:8	Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID1152645	Displacement of [3H]imipramine from human recombinant SERT expressed in CHO cells	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1918193	Dissociation constant, pKa of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID243422	log (1/Km) value for human liver microsome cytochrome P450 3A4	2005	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1675411	Binding affinity to SERT (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.
AID28928	Intrinsic permeability of the compound	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1832394	Microsomal stability in human liver microsome assessed as intrinsic clearance at 0.1 mg/ml incubated upto 1 hour	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID196023	In vitro inhibition of serotonin uptake in synaptosomal preparation of rat brain	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1129953	Toxicity in Kunming mouse assessed as locomotor activity at 10 mg/kg, po measured for 10 mins (Rvb = 1165 +/- 263 cm)	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and biological evaluation of a series of benzoxazole/benzothiazole-containing 2,3-dihydrobenzo[b][1,4]dioxine derivatives as potential antidepressants.
AID377489	Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 15 mg/kg during final 4 mins of the 6 mins session by forced swimming test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID427198	Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID469403	Permeability across PAMPA membrane	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID1529184	Protein binding in immobilized human serum albumin by HPLC analysis	2020	Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4	Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1207659	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID229207	Binding affinity for sigma receptors was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes;NT means not tested.	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID179960	Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID1648400	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as parent compound remaining at 20 uM measured for 60 mins by HPLC/MS analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists.
AID288895	Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 30 mg/kg, ip administered 30 mins before the test in forced-swimming test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID28924	Effective permeability (Pe) across a hexadecane membrane (pH 6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID36851	Concentration of compound for 50% displacement of [3H]WB-4101 from Alpha-1 adrenergic receptor of rat brain	1980	Journal of medicinal chemistry, Aug, Volume: 23, Issue:8	Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID478685	Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID113642	Effect on the antagonism of bicuculline-induced tonic-extensor convulsions (B)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1209253	Drug metabolism in assessed as human CYP1A2-mediated metabolism	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID23975	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID132403	Electrical shock aggression was evaluated in mice, administered intraperitoneally	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1514462	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 120 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID1470742	Anti-depressant like activity in Swiss albino mouse assessed as reduction in immobility time at 60 mg/kg, po measured for 5 mins by tail suspension test	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID1850268	Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay	2022	RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2	Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID119216	Rotation number in mice was determined at 15 minutes after a dose of 10 mg/Kg	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID309524	Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1285114	Half life in human liver microsomes at 0.1 uM up to 60 mins by HPLC-MS/MS analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
AID26310	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID476997	Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID1211796	Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID289402	Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay	2007	Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843	LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID1375640	Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells assessed as decrease in melting	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID293504	Effect on motor co-ordination in Swiss mouse assessed as time on rotating bar at 15 mg/kg, ip after 10 days by Rota-rod test	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1585851	Effective permeability of the compound by PAMPA	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID112145	Effective dose required to prevent reserpine ptosis in mice, administered (po)orally	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1209242	Drug metabolism in assessed as human CYP3A4-mediated maximum rate of reaction per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207218	Inhibition of hERG K channel	2011	Cardiovascular research, Jul-01, Volume: 91, Issue:1	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1636367	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 74.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID624611	Specific activity of expressed human recombinant UGT1A8	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID131718	Effective dose against oxotremorine induced lacrimation	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID117244	Toxicity was measured as LD50,po	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID137278	Reserpine hypothermia antagonism in mouse administered perorally with 5 mg/kg of reserpine 2 hour prior to test compound administration	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID114412	Antidepressant activity to prevent tetrabenazine induced ptosis (TBZ) in mice after intraperitoneal administration	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1209241	Drug metabolism in assessed as human CYP3A4-mediated intrinsic clearance per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID775111	Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test	2013	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21	2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID128144	Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Tetracyclic pyridazines as potential psychopharmacological agents.
AID1332036	Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1480943	Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1437175	Permeability of the compound by PAMPA	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1511118	Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID119032	Percentage protection against NMDA-induced lethality in mice by the compound at 20 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID449472	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 30 mg/kg, ip administered 30 mins before test by forced swimming test	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1144364	Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 5 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID179927	Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179155	Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID222070	Effect on the sleeping time of mice before halothane load (control group);NT means not tested	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID131719	Effective dose against oxotremorine induced tremor	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID288191	Membrane retention in permeability experiment with artificial membrane	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID28236	Unbound fraction (tissues)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID119033	Percentage protection against NMDA-induced lethality in mice by the compound at 40 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID114562	Tested for potentiation of yohimbine toxicity in aggregated mice(Y)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID134215	Tested in vitro for dopamine(DA) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID624612	Specific activity of expressed human recombinant UGT1A9	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID115619	Minimum effective dose causing antagonism of tetrabenazine induced depression in mice was determined when administered perorally	1981	Journal of medicinal chemistry, Feb, Volume: 24, Issue:2	Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID752199	Binding affinity to human serotonin 5-HT transporter by radioligand displacement assay	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID1511119	Permeability of the compound at 25 ug/ml by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1212341	Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID395328	Lipophilicity, log P of the compound	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID112169	Effective dose to reverse tetrabenazine ptosis in mouse when administered po	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents.
AID1207188	Inhibition of voltage-gated L-type Ca channel (species unknown)	2011	Cardiovascular research, Jul-01, Volume: 91, Issue:1	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID309529	Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1209256	Drug metabolism in assessed as human CYP1A2-mediated maximum rate of reaction per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID15708	Plasma clearance for the compound was determined.	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID294623	Antidepressant-like activity in C57BL/6J mouse at 20 mg/kg by tail suspension test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID1627333	Antidepressant activity in CD1(ICR) mouse assessed as decrease in immobility time at 60 mg/kg, po after 1 hr by tail suspension test	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.
AID129176	Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in TBZ treated mice after ip administration	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1209259	Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by optimal design approach	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1444095	Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1703749	Half life in human liver microsomes at 0.1 uM in presence of NADPH by LC/MS/MS analysis	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID1054118	Binding affinity to SERT (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID225960	Minimum effective dose required for inhibition of serotonin uptake was determined by PCA method in rat by peroral administration	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID478679	Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1374547	Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 10 to 20 mg/kg, ip administered 30 mins prior to test measured for last 4 mins of 6 mins observation by forced swim test	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID23976	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID19260	Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID128658	Analgesic activity was determined for delay in response to noxious heat stimuli after subcutaneous administration in mice, in tail flick assay	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID294619	Antidepressant-like activity in Swiss Albino mouse at 20 mg/kg by forced swimming test	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID293498	Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg/day, ip after 10 days by 5-mins swim test	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID91833	Binding affinity against imipramine receptor was determined in homogenized rat cortex tissue using [3H]-imipramine as radioligand	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues.
AID1211298	Dissociation constant, pKa of the compound	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1054120	Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1772562	n-Octanol/PBS buffer distribution coefficient, logD of the compound at pH 7.4	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID224550	Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID566273	Inhibition of human 5-HT transporter	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID681118	TP_TRANSPORTER: transepithelial transport in Caco-2 cells	2003	International journal of pharmaceutics, Sep-16, Volume: 263, Issue:1-2	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
AID28233	Fraction ionized (pH 7.4)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209254	Drug metabolism in assessed as human CYP2C19-mediated intrinsic clearance per mg protein	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID112173	Effective dose was evaluated for its antagonism to reserpine induced hypothermia in mice by intraperitoneal administration	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID115594	Ability to modify turning behavior of mice after intraperitoneal administration	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID243151	Inhibitory concentration against potassium channel HERG	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID48902	Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 3 mg/Kg	2001	Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22	A new class of antiarrhythmic-defibrillatory agents.
AID1054119	Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID113658	Effect on the prolongation of hypoxic survival time (HS)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID363878	Antidepressant activity in albino mouse assessed as decrease in immobility time at 10 mg/kg, ip after 60 mins by forced-swimming test relative to untreated control	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID330664	Effect on life span of Caenorhabditis elegans at 10 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID112365	The compound was tested for antidepressant activity by its ability to reverse tetrabenazine induced ptosis in mice, perorally	1980	Journal of medicinal chemistry, Mar, Volume: 23, Issue:3	Central nervous system activity of 7-substituted 1-azaphenoxathiin analogues and their oxidation products.
AID1636481	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 51.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID361985	Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID114563	Prolongation of hypoxic survival time (HS) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID581808	Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1658711	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as CYP450-mediated drug degradation at 20 uM measured up to 60 mins in presence of NADPH by LC-MS analysis	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Discovery of Novel Nonpeptidic PAR2 Ligands.
AID624607	Specific activity of expressed human recombinant UGT1A3	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID134420	Lethal dose in mouse, in groups of ten	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1322338	Antidepressant-like activity in mouse assessed as immobility time at 5 mg/kg, ip by tail suspension test (Rvb = 154.2 +/- 10.2 sec)
AID639368	Permeability of the compound by PAMPA assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID132107	In vivo effect on Tetrabenazine motor activity in mice following i.p. administration.	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID29337	Ionisation constant (pKa)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID19262	Aqueous solubility	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Prediction of drug solubility from Monte Carlo simulations.
AID24179	logBB, log(C brain/C blood)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID119877	Compound was tested for total number of movements in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1209258	Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by multiple depletion curves method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1305710	Half life in human liver microsomes at 0.1 uM	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID87880	Inhibitory activity against brain adenylate cyclase Histamine H2 receptor	1999	Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16	Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID114922	Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 50 mg/kg	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4	New dibenzothiadiazepine derivatives with antidepressant activities.
AID692188	Therapeutic index, ratio of Cmax in human to IC50 for human OCT2	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID5241	Binding affinity towards 5-hydroxytryptamine 2 receptor	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1677624	Antidepressant activity in mouse assessed as total mean swimming time at 15 mg/kg (Rvb = 2.98 min)	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Synthesis and biological evaluation of imidazoline derivatives as potential CNS and CVS agents.
AID449470	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 10 mg/kg, ip administered 30 mins before test by forced swimming test	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1209250	Drug metabolism in human liver microsomes by multiple depletion curves method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1702358	Antidepressant-like activity in Wistar rat assessed as reduction in immobility time at 10 mg/kg, ip administered 60 mins prior to testing and measured for 5 mins test period by Porsolt-forced swim test
AID1212334	Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of rifampin	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID115754	Minimum effective dose was measured orally by antagonism of tetrabenazine-induced depression in mice(po)	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID225161	Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for repeated administration	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1171393	Oxidative metabolism in human liver microsomes assessed as protein covalent binding measured per mg protein at 10 uM after 1 hr in presence of NADPH	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of (14)C-Labeled Inhibitors of 11β-HSD1.
AID309514	Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg administered 30 mins before the test by forced-swimming test	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID125388	In vitro inhibitory concentration against monoamine oxidase with 5-HT as substrate	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID113646	Effect on the antagonism of nicotine-induced tonic-extensor convulsions (TE) in mice	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID110071	Antagonism of tetrabenazine (TBZ)-induced depression measured in mice by motor activity	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1255972	Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID338197	Displacement of [3H]citalopram from serotonin transporter assessed as specific binding relative to total binding	1993	Journal of natural products, Apr, Volume: 56, Issue:4	The role of receptor binding in drug discovery.
AID1144381	Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 5 mg/kg, po relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Novel analogs of tricyclic psychopharmacological agents.
AID288903	Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg, ip administered 30 mins before the test	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID1207159	Inhibition of Na channel (species unknown)	2011	Cardiovascular research, Jul-01, Volume: 91, Issue:1	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1207249	Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)	2011	Cardiovascular research, Jul-01, Volume: 91, Issue:1	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1390042	Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID620399	Permeability of the compound by PAMPA	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
AID23970	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID27361	Dose of compound required in mg/kg to induce lethality in 50% of mice after 14 days	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4	New dibenzothiadiazepine derivatives with antidepressant activities.
AID62860	Concentration of compound for 50% displacement of [3H]spiperone from Dopamine receptor in rat brain	1980	Journal of medicinal chemistry, Aug, Volume: 23, Issue:8	Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID268084	Metabolic stability in rat liver microsomes	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
AID134634	Antagonism of reserpine-induced hypothermia in mice	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1427528	Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID119097	Rotation number in mice was determined at 12 minutes after a dose of 10 mg/Kg	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID596125	Antidepressant activity in Swiss Sprague-Dawley rat assessed as reduction of immobility time at 15 mg/kg, ip administered 30 mins before test by forced swimming test	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
AID172612	Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1173449	Effective permeability of the compound by PAMPA assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID1353529	Antidepressant like activity in Swiss albino mouse assessed as immobility time at 5 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID60027	Potentiation of the response to norepinephrine was measured	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID114237	Serotonergic activity was determined by measuring the potentiation of 5-hydroxytryptophan in mice upon ip administration	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1346943	Human SERT (Monoamine transporter subfamily)	1993	Journal of natural products, Apr, Volume: 56, Issue:4	The role of receptor binding in drug discovery.
AID1345326	Human M2 receptor (Acetylcholine receptors (muscarinic))	1998	The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2	Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1346501	Mouse Kir3.2 (Inwardly rectifying potassium channels)	2004	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10	Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346535	Mouse Kir3.4 (Inwardly rectifying potassium channels)	2004	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10	Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346732	Human Kv10.1 (Voltage-gated potassium channels)	2004	The Journal of general physiology, Oct, Volume: 124, Issue:4	Mechanism of block of hEag1 K+ channels by imipramine and astemizole.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1801081	Radioligand Binding Assays from Article 10.1111/cbdd.12394: \\Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.\\	2015	Chemical biology & drug design, Mar, Volume: 85, Issue:3	Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017	Wombat Data for BeliefDocking	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6027 (63.54)	18.7374
1990's	1586 (16.72)	18.2507
2000's	963 (10.15)	29.6817
2010's	762 (8.03)	24.3611
2020's	147 (1.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,359 (13.17%)	5.53%
Reviews	485 (4.70%)	6.00%
Case Studies	536 (5.19%)	4.05%
Observational	1 (0.01%)	0.25%
Other	7,939 (76.93%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain[NCT01179828]	Phase 3	150 participants (Actual)	Interventional	2010-07-31	Completed
A Phase II, Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma[NCT04863950]	Phase 2	25 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions[NCT00946764]	Phase 1	48 participants (Actual)	Interventional	2005-07-31	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial[NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters[NCT01028014]		56 participants (Actual)	Interventional	2010-04-30	Completed
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study[NCT04412876]	Phase 3	0 participants (Actual)	Interventional	2020-05-31	Withdrawn(stopped due to Failed to pass the Ministry of Science and Technology.)
Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)[NCT01518634]	Phase 2	138 participants (Actual)	Interventional	2012-01-31	Completed
The Role of Zinc in Therapy of Unipolar Depression[NCT00693680]		60 participants (Actual)	Interventional	2005-01-31	Completed
Dichotic Listening as a Predictor of Medication Response in Depression[NCT00404755]	Phase 4	17 participants (Actual)	Interventional	2006-07-31	Completed
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions[NCT01107353]		39 participants (Actual)	Interventional	2008-08-31	Completed
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression[NCT00296725]	Phase 1/Phase 2	25 participants (Actual)	Interventional	1994-04-30	Completed
[NCT00000504]	Phase 2	0 participants	Interventional	1982-09-30	Completed
Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy[NCT01047488]	Phase 4	75 participants (Anticipated)	Interventional	2010-02-28	Not yet recruiting
Maintenance Therapies in Recurrent Depression-Study I[NCT00227955]	Phase 4	200 participants	Interventional	1987-12-31	Completed
Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects[NCT04520217]	Phase 1	40 participants (Anticipated)	Interventional	2022-06-06	Recruiting
[NCT00000390]	Phase 2	0 participants	Interventional		Completed
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial[NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial[NCT00164775]	Phase 3	107 participants (Actual)	Interventional	2005-06-30	Completed
Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions[NCT00206999]		20 participants (Actual)	Interventional	2004-09-30	Completed
[NCT00000464]	Phase 3	0 participants	Interventional	1987-04-30	Completed
[NCT00000518]	Phase 3	0 participants	Interventional	1985-07-31	Completed
Photodynamic Therapy and Microvesicles[NCT03960125]	Early Phase 1	0 participants (Actual)	Interventional	2021-03-29	Withdrawn(stopped due to The PI decided to move in another direction with his research.)
Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777]	Phase 4	28 participants (Actual)	Interventional	2004-12-31	Completed
Efficacy of Imipramine for Treatment of Patients With Esophageal[NCT01753128]	Phase 3	83 participants (Actual)	Interventional	2012-12-31	Completed
Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy[NCT05688904]	Phase 1	24 participants (Anticipated)	Interventional	2023-01-19	Recruiting
Effect of Single Dose Imipramine on the Urethral and Anal Sphincter in Healthy Women Measured With Urethral Pressure Reflectometry (UPR) and Anal Acoustic Reflectometry (AAR)[NCT03102645]	Phase 1	16 participants (Actual)	Interventional	2017-05-16	Completed
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untreated Breast Cancer (CTMS# 17-0037)[NCT03122444]	Early Phase 1	17 participants (Actual)	Interventional	2019-07-05	Completed
[NCT00004834]		326 participants	Interventional	1998-05-31	Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression[NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy in Women With Stress Urinary Incontinence: a Randomized Controlled Study.[NCT05677295]	Phase 3	90 participants (Anticipated)	Interventional	2023-04-18	Recruiting
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia[NCT04832100]		400 participants (Anticipated)	Observational	2017-08-01	Recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.[NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Psychophysiological Interactions in Non-Cardiac Chest Pain[NCT00005575]	Phase 3	0 participants	Interventional	1999-01-31	Completed
Pharmacovigilance in Gerontopsychiatric Patients[NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	microvolts (Median)
Pseudoephedrine 120mg ER Daily	-18
Solifenacin 5mg Daily	10
Tamsulosin 0.4mg Daily	11
Imipramine 25mg Daily	-15
Cyclobenzaprine 10mg Daily	12
Lactose Capsules, One Daily	36

Intervention	milliliters per second (Median)
Pseudoephedrine 120mg ER Daily	-7.3
Solifenacin 5mg Daily	5.0
Tamsulosin 0.4mg Daily	-5.6
Imipramine 25mg Daily	-6.6
Cyclobenzaprine 10mg Daily	10.3
Lactose Capsules, One Daily	10.4

Intervention	Milliamps (Median)
Pseudoephedrine 120mg ER Daily	0.06
Solifenacin 5mg Daily	0.06
Tamsulosin 0.4mg Daily	-0.8
Imipramine 25mg Daily	-0.12
Cyclobenzaprine 10mg Daily	0.0
Lactose Capsules, One Daily	0.03

Intervention	ng/mL (Mean)
First Imipramine Pamoate, Then Tofranil-PM	11.5
First Tofranil PM, Then Imipramine Pamoate	11.3

Article	Year
Removal of imipramine using advanced oxidation processes: Degradation products and toxicity evolution. Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering, Volume: 58, Issue: 4	2023
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects. International journal of molecular sciences, Nov-01, Volume: 22, Issue: 21	2021
An approach to evaluate metabolite-related phototoxicity with combined use of photochemical properties and skin deposition. Toxicology letters, Oct-10, Volume: 350	2021
Antidepressant Imipramine Protects Bupivacaine-Induced Neurotoxicity in Dorsal Root Ganglion Neurons Through Coactivation of TrkA and TrkB. Journal of cellular biochemistry, Volume: 118, Issue: 11	2017
Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. The International journal of risk & safety in medicine, Sep-17, Volume: 28, Issue: 3	2016
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue: 16	2016
Compounded ointment results in severe toxicity in a pediatric patient. Pediatric emergency care, Volume: 29, Issue: 11	2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, Oct-15, Volume: 25, Issue: 10	2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, Volume: 7, Issue: 12	2011
Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine. Phytomedicine : international journal of phytotherapy and phytopharmacology, Feb-15, Volume: 19, Issue: 3-4	2012
In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs. Chemical research in toxicology, Sep-20, Volume: 23, Issue: 9	2010
Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnesium research, Volume: 21, Issue: 4	2008
In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit F Tests. Archives of environmental contamination and toxicology, Volume: 54, Issue: 2	2008
[Review of pharmacological efficacies and side effects of antidepressants]. Nihon rinsho. Japanese journal of clinical medicine, Volume: 65, Issue: 9	2007
Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. International clinical psychopharmacology, Volume: 22, Issue: 5	2007
Differential neurotoxicity of tricyclic antidepressants and novel derivatives in vitro in a dorsal root ganglion cell culture model. European journal of anaesthesiology, Volume: 24, Issue: 8	2007
A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. The American journal of psychiatry, Volume: 164, Issue: 2	2007
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert opinion on drug safety, Volume: 4, Issue: 2	2005
Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. Journal of neurochemistry, Volume: 92, Issue: 5	2005
THE INCREASE IN THE TOXICITY OF YOHIMBINE INDUCED BY IMIPRAMINE AND OTHER DRUGS IN MICE. British journal of pharmacology and chemotherapy, Volume: 21	1963
A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. The international journal of neuropsychopharmacology, Volume: 5, Issue: 4	2002
Bioelectric toxicity caused by chlorpromazine in human lung epithelial cells. Toxicology and applied pharmacology, Sep-15, Volume: 183, Issue: 3	2002
Specific side effects of long-term imipramine management of panic disorder. Journal of clinical psychopharmacology, Volume: 22, Issue: 2	2002
Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. International psychogeriatrics, Volume: 13, Issue: 1	2001
The side effects burden of extended imipramine treatment of panic disorder. Journal of clinical psychopharmacology, Volume: 20, Issue: 5	2000
Reboxetine: tolerability and safety profile in patients with major depression. Acta psychiatrica Scandinavica. Supplementum, Volume: 402	2000
Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. British journal of pharmacology, Volume: 130, Issue: 4	2000
Attitudes about antidepressants: influence of information about weight-related side effects. Perceptual and motor skills, Volume: 90, Issue: 2	2000
6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. Journal of neural transmission (Vienna, Austria : 1996), Volume: 107, Issue: 3	2000
Mechanisms of Ca2+ antagonism in imipramine-induced toxicity of isolated adult rat cardiomyocytes. Toxicology and applied pharmacology, Volume: 153, Issue: 1	1998
Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. Pharmacology, Volume: 57, Issue: 5	1998
Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta psychiatrica Scandinavica, Volume: 97, Issue: 2	1998
Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychological medicine, Volume: 28, Issue: 1	1998
Side effects of adjunct light therapy in patients with major depression. European archives of psychiatry and clinical neuroscience, Volume: 247, Issue: 5	1997
Studies on the neurotoxicity of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in SH-SY5Y cells. European journal of pharmacology, Dec-07, Volume: 293, Issue: 4	1995
[Adverse effects: priapism caused by paroxetine]. Annales medico-psychologiques, Volume: 154, Issue: 2	1996
The safety profile of nefazodone. The Journal of clinical psychiatry, Volume: 57 Suppl 2	1996
Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 4, Issue: 1	1994
Magnesium potentiates imipramine toxicity in the isolated rat heart. Annals of emergency medicine, Volume: 24, Issue: 2	1994
Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of clinical psychopharmacology, Volume: 14, Issue: 5	1994
Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Neuropsychobiology, Volume: 31, Issue: 2	1995
Cardiac toxicity in an adolescent following chronic lithium and imipramine therapy. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, Volume: 14, Issue: 5	1993
Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression? Neuropsychobiology, Volume: 32, Issue: 1	1995
Imipramine cardiotoxicity: an electrocardiographic and haemodynamic study in rabbits. Acta pharmacologica et toxicologica, Volume: 46, Issue: 3	1980
Lack of anticholinergic side effects with a new antidepressent--trazodone. The Journal of clinical psychiatry, Volume: 41, Issue: 3	1980
Plasma levels of imipramine and adverse effects in children. The American journal of psychiatry, Volume: 140, Issue: 10	1983
Safety and efficacy of bupropion in elderly patients: preliminary observations. The Journal of clinical psychiatry, Volume: 44, Issue: 5 Pt 2	1983
Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population. Psychopathology, Volume: 17 Suppl 2	1984
An overview of side effects and long-term experience with nomifensine from United States clinical trials. The Journal of clinical psychiatry, Volume: 45, Issue: 4 Pt 2	1984
A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. The Journal of clinical psychiatry, Volume: 45, Issue: 4 Pt 2	1984
Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. The Journal of clinical psychiatry, Volume: 45, Issue: 4 Pt 2	1984
Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate. The American journal of psychiatry, Volume: 140, Issue: 8	1983
Use of statistics in the analysis of side effect data from clinical trials of psychoactive agents. Progress in neuro-psychopharmacology & biological psychiatry, Volume: 6, Issue: 4-6	1982
Treatment of haemodynamic and electrocardiographic side-effects resulting from imipramine toxicity in rats and dogs. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 330, Issue: 2	1985
Profound behavioral toxicity due to tricyclic antidepressants. The Journal of nervous and mental disease, Volume: 174, Issue: 10	1986
Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, Volume: 31, Issue: 4	1986
Genotoxicity evaluation of the tricyclic antidepressants amitriptyline and imipramine using human lymphocyte cultures. Environmental and molecular mutagenesis, Volume: 12, Issue: 4	1988
Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine. The Journal of clinical psychiatry, Volume: 49, Issue: 10	1988
Ca2+ modulators as antidotes to imipramine and neurotransmitter toxicity. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), Volume: 185, Issue: 4	1987
The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. Journal of clinical psychopharmacology, Volume: 9, Issue: 3	1989
Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. The Journal of clinical psychiatry, Volume: 51 Suppl	1990
Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria. Journal of neural transmission. Supplementum, Volume: 32	1990
Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutation research, Volume: 260, Issue: 1	1991
Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta psychiatrica Scandinavica. Supplementum, Volume: 365	1991
Amitriptyline prevents N-methyl-D-aspartate (NMDA)-induced toxicity, does not prevent NMDA-induced elevations of extracellular glutamate, but augments kainate-induced elevations of glutamate. Journal of neurochemistry, Volume: 59, Issue: 2	1992
Cardiovascular side effects of tricyclic antidepressants - a risk in the use of these drugs. International journal of clinical pharmacology and biopharmacy, Volume: 11, Issue: 3	1975
Imipramine toxicity. The Journal of urology, Volume: 114, Issue: 3	1975
Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Australian and New Zealand journal of medicine, Volume: 5, Issue: 1	1975
Imipramine enhancement of pentobarbital toxicity in rats. Research communications in chemical pathology and pharmacology, Volume: 13, Issue: 3	1976
The relative toxicity of amitriptyline, imipramine, maprotiline and mianserin in rabbits in vivo. British journal of pharmacology, Volume: 65, Issue: 2	1979
Acute cardiovascular toxicity of trazodone, etoperidone and imipramine in rats. Toxicology, Volume: 10, Issue: 2	1978
Toxoplasmosis masquerading as a psychotropic side effect. The Journal of clinical psychiatry, Volume: 39, Issue: 7	1978
Relative toxicity of amitriptyline, imipramine, maprotiline and mianserin after intravenous infusion in conscious rabbits. British journal of clinical pharmacology, Volume: 5 Suppl 1	1978
Potentiation of tricyclic antidepressant toxicity by physostigmine in mice. Clinical toxicology, Volume: 11, Issue: 4	1977
Comparison of the cardiovascular toxicity of three tricyclic antidepressant drugs: imipramine, amitriptyline, and doxepin. Clinical toxicology, Volume: 14, Issue: 3	1979
Cardiovascular side effects of long-term therapy with tricyclic antidepressants in the aged. Journal of the American Geriatrics Society, Volume: 27, Issue: 5	1979
Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants. Pharmacology, Volume: 18, Issue: 2	1979
Trazodone, a new antidepressant: efficacy and safety in endogenous depression. The Journal of clinical psychiatry, Volume: 40, Issue: 9	1979
Effect of membrane stabilizing agents on induction of the immune response. II. Inhibitory effects on lymphocyte activation by B-cell mitogens parallel toxicity. Scandinavian journal of immunology, Volume: 7, Issue: 2	1978
Comparative cardiovascular toxicity of trazodone and imipramine in the rat. Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, Issue: 1	1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
An in-depth analysis of four classes of antidepressants quantification from human serum using LC-MS/MS. Scientific reports, 02-06, Volume: 13, Issue: 1	2023
Pro-cognitive effect of acute imipramine administration correlates with direct interaction of BDNF with its receptor, Trkβ. Brain research, 08-15, Volume: 1789	2022
Disturbance of prefrontal cortical myelination in olfactory bulbectomized mice is associated with depressive-like behavior. Neurochemistry international, Volume: 148	2021
Intermittent repeated stress but not ketamine changes mice response to antidepressants. Neuroscience letters, 01-10, Volume: 741	2021
NS398, a cyclooxygenase-2 inhibitor, reverses memory performance disrupted by imipramine in C57Bl/6J mice. Brain research, 05-01, Volume: 1734	2020
Adaptive mechanisms following antidepressant drugs: Focus on serotonin 5-HT Pharmacological reports : PR, Volume: 71, Issue: 6	2019
Role of 5-HT2C receptors of the dorsal hippocampus in the modulation of anxiety- and panic-related defensive responses in rats. Neuropharmacology, Volume: 148	2019
Evaluation of the effectiveness of chronic antidepressant drug treatments in the hippocampal mitochondria - A proteomic study in an animal model of depression. Progress in neuro-psychopharmacology & biological psychiatry, 08-01, Volume: 78	2017
The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression. Molecular neurobiology, Volume: 53, Issue: 10	2016
Alterations in behavioral responses to dopamine agonists in olfactory bulbectomized mice: relationship to changes in the striatal dopaminergic system. Psychopharmacology, Volume: 233, Issue: 7	2016
The effect of imipramine, ketamine, and zinc in the mouse model of depression. Metabolic brain disease, Volume: 30, Issue: 6	2015
Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications. Translational psychiatry, Jun-02, Volume: 5	2015
The effects of antidepressants "fluoxetine and imipramine" on vascular abnormalities and Toll like receptor-4 expression in diabetic and non-diabetic rats exposed to chronic stress. PloS one, Volume: 10, Issue: 3	2015
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Behavioural brain research, Feb-01, Volume: 278	2015
Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacology, biochemistry, and behavior, Volume: 126	2014
[Studying the development of imipramine tolerance and prospects of its overcoming with the aid of tianeptine]. Eksperimental'naia i klinicheskaia farmakologiia, Volume: 77, Issue: 5	2014
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. Behavioural brain research, Sep-01, Volume: 271	2014
Plurality of anxiety and depression alteration mechanism by oleanolic acid. Journal of psychopharmacology (Oxford, England), Volume: 28, Issue: 10	2014
Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotoxicity research, Volume: 26, Issue: 2	2014
Chronic administration of imipramine but not agomelatine and moclobemide affects the nitrergic relaxation of rabbit corpus cavernosum smooth muscle. European journal of pharmacology, Aug-15, Volume: 714, Issue: 1-3	2013
Long-term antidepressant treatment inhibits neuropathic pain-induced CREB and PLCγ-1 phosphorylation in the mouse spinal cord dorsal horn. The journal of pain, Volume: 14, Issue: 10	2013
The influences of reserpine and imipramine on the 5-HT2 receptor binding site and its coupled second messenger in rat cerebral cortex. The Chinese journal of physiology, Aug-31, Volume: 56, Issue: 4	2013
Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice. PloS one, Volume: 8, Issue: 4	2013
The differential effects of chronic imipramine or citalopram administration on physiological and behavioral outcomes in naïve mice. Behavioural brain research, May-15, Volume: 245	2013
N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Progress in neuro-psychopharmacology & biological psychiatry, Dec-03, Volume: 39, Issue: 2	2012
Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior. Neuroscience, May-17, Volume: 210	2012
Electroconvulsive seizure, but not imipramine, rapidly up-regulates pro-BDNF and t-PA, leading to mature BDNF production, in the rat hippocampus. The international journal of neuropsychopharmacology, Volume: 16, Issue: 2	2013
Short-term individual housing induced social deficits in female Mongolian gerbils: attenuation by chronic but not acute imipramine. Neuropharmacology, Volume: 62, Issue: 5-6	2012
Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain research bulletin, Apr-05, Volume: 81, Issue: 6	2010
Chronic administration of imipramine normalizes decreased sexual motivation and increased predisposition to catalepsy induced by propylthiouracil in rats. Neuroscience and behavioral physiology, Volume: 39, Issue: 4	2009
Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic & clinical pharmacology & toxicology, Volume: 103, Issue: 6	2008
Contrasting effects of acute and chronic treatment with imipramine and fluoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze. Brain research bulletin, Mar-30, Volume: 78, Issue: 6	2009
Pyridoxine effect on the antidepressant action of imipramine in albino mice. Saudi medical journal, Volume: 29, Issue: 11	2008
Anxiolytic-like effect of chronic treatment with Erythrina velutina extract in the elevated plus-maze test. Journal of ethnopharmacology, Jul-23, Volume: 118, Issue: 2	2008
Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram. European journal of pharmacology, Mar-31, Volume: 583, Issue: 1	2008
Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. European journal of pharmacology, Mar-31, Volume: 583, Issue: 1	2008
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? Pharmacology, biochemistry, and behavior, Volume: 89, Issue: 3	2008
Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders. Behavioural brain research, May-16, Volume: 189, Issue: 1	2008
Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biological & pharmaceutical bulletin, Volume: 31, Issue: 2	2008
Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze. Journal of psychopharmacology (Oxford, England), Volume: 22, Issue: 2	2008
Dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy. Neuroscience and behavioral physiology, Volume: 38, Issue: 2	2008
Increased DOI-induced wet-dog shakes in adrenocorticotropic hormone-treated rats are not affected by chronic imipramine treatment: possible involvement of enhanced 5-HT(2A)-receptor expression in the frontal cortex. Journal of pharmacological sciences, Volume: 106, Issue: 1	2008
Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. European journal of pharmacology, Aug-13, Volume: 569, Issue: 1-2	2007
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats. European journal of pharmacology, Jun-22, Volume: 565, Issue: 1-3	2007
Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam The Journal of pharmacology and experimental therapeutics, Volume: 321, Issue: 1	2007
Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biological psychiatry, Apr-15, Volume: 61, Issue: 8	2007
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behavioural pharmacology, Volume: 17, Issue: 7	2006
Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British journal of pharmacology, Volume: 149, Issue: 5	2006
Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. European journal of pharmacology, Jul-10, Volume: 541, Issue: 1-2	2006
G(olf) protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy. Life sciences, Jun-27, Volume: 79, Issue: 5	2006
Announced rewards counteract the impairment of anticipatory behaviour in socially stressed rats. Behavioural brain research, Jun-20, Volume: 161, Issue: 2	2005
Influence of imipramine on the duration of immobility in chronic forced-swim-stressed rats. Acta medica Okayama, Volume: 58, Issue: 6	2004
Stress-induced c-Fos expression is differentially modulated by dexamethasone, diazepam and imipramine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 30, Issue: 7	2005
Chronic administration of imipramine decreases freezing time in rats genetically predisposed to catalepsy. Bulletin of experimental biology and medicine, Volume: 138, Issue: 4	2004
[Effect of madecassoside on depression behavior of mice and activities of MAO in different brain regions of rats]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, Volume: 2, Issue: 6	2004
5-HT(1A) receptor full agonist, 8-OH-DPAT, exerts antidepressant-like effects in the forced swim test in ACTH-treated rats. European journal of pharmacology, Nov-14, Volume: 481, Issue: 1	2003
Imipramine-associated hyperpigmentation. The Annals of pharmacotherapy, Volume: 37, Issue: 6	2003
Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. Brain research, Dec-20, Volume: 958, Issue: 1	2002
Effect of chronic administration of imipramine on 2A-serotonin receptor mRNA in brain cortex of rats predisposed and resistant to catalepsy. Bulletin of experimental biology and medicine, Volume: 134, Issue: 2	2002
Effects of imipramine and lithium on wet-dog shakes mediated by the 5-HT2A receptor in ACTH-treated rats. Pharmacology, biochemistry, and behavior, Volume: 72, Issue: 1-2	2002
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. Synapse (New York, N.Y.), Volume: 43, Issue: 1	2002
Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life sciences, Sep-07, Volume: 69, Issue: 16	2001
Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 11, Issue: 5	2001
St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Molecular psychiatry, Volume: 6, Issue: 5	2001
Characteristics of depressive behavior induced by feeding thiamine-deficient diet in mice. Life sciences, Jul-27, Volume: 69, Issue: 10	2001
Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression. Molecular psychiatry, Volume: 6, Issue: 4	2001
Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2. Life sciences, Dec-29, Volume: 68, Issue: 6	2000
Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology, Volume: 152, Issue: 3	2000
Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex--a possible mechanism of neuroprotection in major depression? Neuroscience, Volume: 100, Issue: 4	2000
The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behavioural brain research, Volume: 115, Issue: 1	2000
Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Molecular psychiatry, Volume: 5, Issue: 4	2000
Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biological psychiatry, Sep-15, Volume: 46, Issue: 6	1999
Alnespirone (S 20499), an agonist of 5-HT1A receptors, and imipramine have similar activity in a chronic mild stress model of depression. Pharmacology, biochemistry, and behavior, Volume: 63, Issue: 4	1999
The effect of chronic administration of antidepressants on the circadian pattern of corticosterone in the rat. Psychopharmacology, Volume: 140, Issue: 2	1998
Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. Journal of molecular neuroscience : MN, Volume: 10, Issue: 3	1998
Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. Pharmacology, Volume: 57, Issue: 5	1998
Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants? European journal of pharmacology, Oct-22, Volume: 337, Issue: 2-3	1997
Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacology, biochemistry, and behavior, Volume: 58, Issue: 4	1997
Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biological psychiatry, Oct-15, Volume: 42, Issue: 8	1997
Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. The Journal of clinical endocrinology and metabolism, Volume: 82, Issue: 8	1997
Imipramine-induced changes in 5-HT2 receptor sites and inositoltrisphosphate levels in rat brain. Neurochemical research, Volume: 22, Issue: 9	1997
[A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, Volume: 17, Issue: 2	1997
Regulation of c-Fos and NGF1-A by antidepressant treatments. Synapse (New York, N.Y.), Volume: 25, Issue: 4	1997
Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels. Neuropharmacology, Volume: 35, Issue: 9-10	1996
Imipramine distribution among red blood cells, plasma and brain tissue. General physiology and biophysics, Volume: 15, Issue: 1	1996
Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Chronobiology international, Volume: 13, Issue: 4	1996
Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology, Volume: 112, Issue: 3	1995
A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat. Journal of pharmaceutical sciences, Volume: 85, Issue: 3	1996
Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. The Journal of pharmacology and experimental therapeutics, Volume: 277, Issue: 2	1996
Persistence of chronic mood disorders: a 2 year follow-up. Psychiatry and clinical neurosciences, Volume: 49, Issue: 1	1995
Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience, Apr-01, Volume: 16, Issue: 7	1996
Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine. Progress in neuro-psychopharmacology & biological psychiatry, Volume: 19, Issue: 5	1995
Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain research. Molecular brain research, Volume: 17, Issue: 1-2	1993
p-chlorophenylalanine-reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. European journal of pharmacology, Jun-11, Volume: 237, Issue: 1	1993
Evaluation of depression in rats exposed to chronic (unpredictable) electric shock. Pharmacology, biochemistry, and behavior, Volume: 46, Issue: 3	1993
Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine and mianserin, on the social behaviour of mice. Neuropharmacology, Volume: 33, Issue: 6	1994
Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology, Volume: 115, Issue: 4	1994
Design of a desipramine dosing regimen for the rapid induction and maintenance of maximal cortical beta-adrenoceptor downregulation. Neuropharmacology, Volume: 33, Issue: 9	1994
Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. European journal of pharmacology, Sep-22, Volume: 263, Issue: 1-2	1994
Chronic imipramine administration alters the activity and phosphorylation state of tyrosine hydroxylase in dopaminergic regions of rat brain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 12, Issue: 2	1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical research, Volume: 40, Issue: 3	2023
Selective drug metabolite trace analysis by very high-volume injections and heartcut two-dimensional (2D)-ultrahigh performance liquid chromatography (UHPLC). Journal of chromatography. A, Sep-13, Volume: 1601	2019
An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates. Drug metabolism and disposition: the biological fate of chemicals, Volume: 45, Issue: 10	2017
The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine. Drug metabolism and disposition: the biological fate of chemicals, Volume: 44, Issue: 10	2016
The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans. Antimicrobial agents and chemotherapy, Volume: 56, Issue: 10	2012
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs. Drug metabolism and disposition: the biological fate of chemicals, Volume: 40, Issue: 1	2012
Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry. Biological & pharmaceutical bulletin, Volume: 34, Issue: 8	2011
Kinetic studies of drug-protein interactions by using peak profiling and high-performance affinity chromatography: examination of multi-site interactions of drugs with human serum albumin columns. Journal of chromatography. A, Apr-15, Volume: 1218, Issue: 15	2011
A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. Journal of pharmaceutical sciences, Volume: 99, Issue: 8	2010
Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, Oct-15, Volume: 50, Issue: 3	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, Aug-13, Volume: 52, Issue: 15	2009
First-principle, structure-based prediction of hepatic metabolic clearance values in human. European journal of medicinal chemistry, Volume: 44, Issue: 4	2009
Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 378, Issue: 1	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, Volume: 36, Issue: 7	2008
Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. European journal of pharmacology, Mar-31, Volume: 583, Issue: 1	2008
New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition. Biopharmaceutics & drug disposition, Volume: 29, Issue: 1	2008
Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug metabolism and disposition: the biological fate of chemicals, Volume: 35, Issue: 8	2007
Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug metabolism and disposition: the biological fate of chemicals, Volume: 34, Issue: 11	2006
Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. Pharmacology, biochemistry, and behavior, Volume: 81, Issue: 3	2005
Single and multiple dose pharmacokinetic evaluation of a transdermal delivery system of imipramine hydrochloride. Arzneimittel-Forschung, Volume: 55, Issue: 4	2005
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, Feb-26, Volume: 47, Issue: 5	2004
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of medicinal chemistry, Jun-20, Volume: 45, Issue: 13	2002
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Journal of clinical psychopharmacology, Volume: 22, Issue: 2	2002
A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs. Biological & pharmaceutical bulletin, Volume: 24, Issue: 5	2001
Pharmacokinetics of imipramine in narcoleptic horses. American journal of veterinary research, Volume: 62, Issue: 5	2001
Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. The Journal of pharmacy and pharmacology, Volume: 52, Issue: 12	2000
Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. British journal of pharmacology, Volume: 131, Issue: 2	2000
Effects of imipramine, an uptake inhibitor, on double-peaked constrictor responses to periarterial nerve stimulation in isolated, perfused canine splenic arteries. Japanese journal of pharmacology, Volume: 79, Issue: 4	1999
Clinical pharmacokinetics of acamprosate. Clinical pharmacokinetics, Volume: 35, Issue: 5	1998
Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet (London, England), Jan-31, Volume: 351, Issue: 9099	1998
Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychological medicine, Volume: 28, Issue: 1	1998
Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug metabolism and disposition: the biological fate of chemicals, Volume: 25, Issue: 12	1997
The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical pharmacology and therapeutics, Volume: 62, Issue: 2	1997
Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. British journal of clinical pharmacology, Volume: 44, Issue: 2	1997
Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine. Pharmacology & toxicology, Volume: 80, Issue: 6	1997
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. British journal of clinical pharmacology, Volume: 43, Issue: 3	1997
A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat. Journal of pharmaceutical sciences, Volume: 85, Issue: 3	1996
Effect of jet ventilation on heart failure: decreased afterload but negative response in left ventricular end-systolic pressure-volume function. Critical care medicine, Volume: 24, Issue: 4	1996
Lack of pharmacokinetic interaction between chloroquine and imipramine. Therapeutic drug monitoring, Volume: 15, Issue: 1	1993
Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Therapeutic drug monitoring, Volume: 15, Issue: 3	1993
Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. British journal of pharmacology, Volume: 112, Issue: 2	1994
Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man. Fundamental & clinical pharmacology, Volume: 8, Issue: 3	1994
The pharmacodynamics of desipramine and desmethyldesipramine in rats. The Journal of pharmacology and experimental therapeutics, Volume: 270, Issue: 2	1994
Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 317, Issue: 3	1981
The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. The American journal of psychiatry, Volume: 137, Issue: 6	1980
Effect of deuteration of imipramine on its pharmacokinetic properties in the rat. Biochemical pharmacology, Feb-15, Volume: 32, Issue: 4	1983
Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Psychopharmacology, Volume: 70, Issue: 1	1980
Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. The Journal of pharmacology and experimental therapeutics, Volume: 229, Issue: 3	1984
Pharmacodynamics of nomifensine: a review of studies in healthy subjects. The Journal of clinical psychiatry, Volume: 45, Issue: 4 Pt 2	1984
[Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry]. Wiener klinische Wochenschrift, Jul-08, Volume: 95, Issue: 14	1983
Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics. Advances in biochemical psychopharmacology, Volume: 39	1984
The contribution of pharmacokinetics to the best use of benzodiazepines and antidepressants. L'Encephale, Volume: 8, Issue: 2	1982
Pharmacokinetic interaction of disulfiram and antidepressants. The American journal of psychiatry, Volume: 142, Issue: 11	1985
Lack of effect of oral activated charcoal on imipramine clearance. Clinical pharmacology and therapeutics, Volume: 38, Issue: 3	1985
An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clinical pharmacology and therapeutics, Volume: 42, Issue: 4	1987
Pharmacokinetic profiles and temporal changes in quantitative EEG after imipramine administrations. The Japanese journal of psychiatry and neurology, Volume: 41, Issue: 1	1987
Effects of quinupramine on the central monoamine uptake systems and involvement of pharmacokinetics in its pharmacological activities. Japanese journal of pharmacology, Volume: 45, Issue: 2	1987
[Drug interaction of imipramine hydrochloride to the pharmacodynamics and pharmacokinetics of oxazepam]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, Volume: 90, Issue: 3	1987
Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clinical pharmacology and therapeutics, Volume: 43, Issue: 5	1988
Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. Journal of clinical psychopharmacology, Volume: 8, Issue: 1	1988
Compliance during tricyclic antidepressant therapy: pharmacokinetic and analytical issues. Clinical chemistry, Volume: 34, Issue: 5	1988
Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review. Clinical chemistry, Volume: 34, Issue: 5	1988
Imipramine treatment alters the pharmacokinetics and pharmacodynamics of diazepam. Journal of pharmaceutical sciences, Volume: 76, Issue: 12	1987
Imipramine: a model substance in pharmacokinetic research. Acta psychiatrica Scandinavica. Supplementum, Volume: 345	1988
[Physiological principles of imipramine pharmacokinetics]. Folia medica Cracoviensia, Volume: 30, Issue: 3-4	1989
Effects of lithium on alterations of pharmacokinetics of imipramine and on the related changes of monoamines in rat brain. European journal of pharmacology, Dec-07, Volume: 173, Issue: 2-3	1989
Correlative changes of serotonin and catecholamines with pharmacokinetic alterations of imipramine in rat brain. European journal of pharmacology, Jun-20, Volume: 165, Issue: 2-3	1989
Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. Journal of studies on alcohol, Volume: 51, Issue: 4	1990
Vinpocetine therapy does not change imipramine pharmacokinetics in man. International journal of clinical pharmacology, therapy, and toxicology, Volume: 28, Issue: 3	1990
Imipramine pharmacokinetics in depressed geriatric patients. International journal of clinical pharmacology research, Volume: 10, Issue: 3	1990
Clinical pharmacokinetics of imipramine and desipramine. Clinical pharmacokinetics, Volume: 18, Issue: 5	1990
Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. DICP : the annals of pharmacotherapy, Volume: 25, Issue: 12	1991
Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. Chronobiology international, Volume: 8, Issue: 3	1991
Population pharmacokinetics of imipramine in children. European journal of clinical pharmacology, Volume: 43, Issue: 1	1992
Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine. Psychopharmacology, Volume: 109, Issue: 1-2	1992
A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine. The Journal of pharmacy and pharmacology, Volume: 44, Issue: 5	1992
Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. Clinical chemistry, Volume: 22, Issue: 6	1976
Pharmacokinetics of bethanidine in hypertensive patients. Clinical pharmacology and therapeutics, Volume: 17, Issue: 3	1975
Effects of thioridazine and diazepam on the pharmacokinetics of [14C]imipramine in rat: acute study. The Journal of pharmacy and pharmacology, Volume: 27, Issue: 7	1975
Imipramine hydrochloride: pharmacodynamic effects on lower urinary tract of female dogs. Urology, Volume: 6, Issue: 1	1975
Cholinergic and adrenergic neuroreceptors in urinary tract of female dogs. Evaluation of function with pharmacodynamics. Urology, Volume: 5, Issue: 5	1975
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry research, Volume: 44, Issue: 3	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials. Journal of affective disorders, 06-15, Volume: 307	2022
Can the combined treatment of solifenacin and imipramine has a role in desmopressin refractory monosymptomatic nocturnal enuresis? A prospective double-blind randomized placebo-controlled study. Urologia, Volume: 88, Issue: 4	2021
Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice. Chronobiology international, Volume: 36, Issue: 9	2019
Zanthoxylum alatum abrogates lipopolysaccharide-induced depression-like behaviours in mice by modulating neuroinflammation and monoamine neurotransmitters in the hippocampus. Pharmaceutical biology, Volume: 56, Issue: 1	2018
Imipramine for refractory daytime incontinence in the pediatric population. Journal of pediatric urology, Volume: 14, Issue: 1	2018
The anxiolytic-like effect of 6-styryl-2-pyrone in mice involves GABAergic mechanism of action. Metabolic brain disease, Volume: 33, Issue: 1	2018
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. Pakistan journal of pharmaceutical sciences, Volume: 29, Issue: 6 Suppl	2016
The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. Behavioural pharmacology, Volume: 28, Issue: 1	2017
The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine. Drug metabolism and disposition: the biological fate of chemicals, Volume: 44, Issue: 10	2016
Absolute quantification of imipramine and its metabolites in vivo utilizing calibrators from radiolabeled in vitro incubations. Bioanalysis, Volume: 8, Issue: 4	2016
Acute and Chronic Treatments with Quetiapine Increase Mitochondrial Respiratory Chain Complex Activity in the Rat Brain. Current neurovascular research, Volume: 12, Issue: 3	2015
Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain, Volume: 156, Issue: 5	2015
Putative biomarker for phospholipid accumulation in cultured cells treated with phospholipidosis-inducing drugs: alteration of the phosphatidylinositol composition detected using high-performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Sep-15, Volume: 967	2014
Lasting downregulation of the lipid peroxidation enzymes in the prefrontal cortex of mice susceptible to stress-induced anhedonia. Behavioural brain research, Jan-01, Volume: 276	2015
Novel neurological and immunological targets for salicylate-based phytopharmaceuticals and for the anti-depressant imipramine. Phytomedicine : international journal of phytotherapy and phytopharmacology, Jul-15, Volume: 19, Issue: 10	2012
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, Volume: 16, Issue: 15-16	2011
Determination of imipramine and trimipramine by capillary electrophoresis with electrochemiluminescence detection. Talanta, Feb-15, Volume: 83, Issue: 5	2011
Automated experimental system capturing three behavioral components during murine forced swim test. Life sciences, Feb-28, Volume: 88, Issue: 9-10	2011
Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant? The Journal of family practice, Volume: 59, Issue: 3	2010
Natural history, symptoms and treatment of the narcoleptic syndrome. Acta neurologica Scandinavica, Volume: 52, Issue: 5	1975
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. European journal of pharmacology, Jan-14, Volume: 602, Issue: 2-3	2009
Forced swimming and imipramine modify plasma and brain amino acid concentrations in mice. European journal of pharmacology, Jan-05, Volume: 602, Issue: 1	2009
Modelling the anxiety-depression continuum in chicks. Journal of psychopharmacology (Oxford, England), Volume: 23, Issue: 2	2009
Efficacy of imipramine in psychotic versus nonpsychotic depression. Journal of clinical psychopharmacology, Volume: 28, Issue: 2	2008
Adequacy of continuation and maintenance treatments for major depression in Japan. Journal of psychopharmacology (Oxford, England), Volume: 22, Issue: 2	2008
Fast urinary screening for imipramine and desipramine using on-line solid-phase extraction and selective derivatization. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Oct-01, Volume: 857, Issue: 2	2007
Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. The Journal of clinical psychiatry, Volume: 68, Issue: 6	2007
Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. European journal of pharmacology, Aug-13, Volume: 569, Issue: 1-2	2007
Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Canadian journal of psychiatry. Revue canadienne de psychiatrie, Volume: 52, Issue: 1	2007
Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies. Journal of neuroscience methods, Jun-15, Volume: 163, Issue: 1	2007
Piloerection induced by replacing fluvoxamine with milnacipran. British journal of clinical pharmacology, Volume: 63, Issue: 6	2007
Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam The Journal of pharmacology and experimental therapeutics, Volume: 321, Issue: 1	2007
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie, Volume: 51, Issue: 12	2006
Delayed effects of antidepressant drugs in rats. Behavioural pharmacology, Volume: 17, Issue: 8	2006
[Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition]. Tijdschrift voor psychiatrie, Volume: 48, Issue: 4	2006
Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. The Journal of clinical psychiatry, Volume: 67, Issue: 2	2006
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biological psychiatry, May-01, Volume: 59, Issue: 9	2006
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? Psychopharmacology, Volume: 181, Issue: 3	2005
[Effect of madecassoside on depression behavior of mice and activities of MAO in different brain regions of rats]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, Volume: 2, Issue: 6	2004
Excess fatality from desipramine and dosage recommendations. Therapeutic drug monitoring, Volume: 26, Issue: 5	2004
Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. PharmacoEconomics, Volume: 18, Issue: 4	2000
Determination of imipramine in presence of iminodibenzyl and in pharmaceutical dosage form. Journal of pharmaceutical and biomedical analysis, Nov-24, Volume: 33, Issue: 4	2003
Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacological research, Volume: 48, Issue: 2	2003
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain research, Jan-03, Volume: 959, Issue: 1	2003
[Manic state during the addition of lithium in the case of depression resistant to imipramine]. Nederlands tijdschrift voor geneeskunde, Nov-09, Volume: 146, Issue: 45	2002
Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, Volume: 69, Issue: 4	2002
[Chronobiological research on antidepressant drugs: the effect of the antidepressant drugs, trazodone and imipramine on the circadian rhythm using electroencephalography in healthy volunteers]. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, Volume: 69, Issue: 3	2002
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Journal of clinical psychopharmacology, Volume: 22, Issue: 2	2002
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of general psychiatry, Volume: 59, Issue: 3	2002
Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens. Pharmacopsychiatry, Volume: 34 Suppl 1	2001
Pharmacokinetics of imipramine in narcoleptic horses. American journal of veterinary research, Volume: 62, Issue: 5	2001
Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology, Volume: 154, Issue: 1	2001
Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. The Journal of clinical psychiatry, Volume: 61, Issue: 4	2000
Treatment of attention-deficit/hyperactivity disorder. Evidence report/technology assessment (Summary), Issue: 11	1999
Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 9, Issue: 6	1999
Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry, Volume: 32, Issue: 3	1999
[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?]. L'Encephale, Volume: 25 Spec No 2	1999
Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. International journal of psychiatry in medicine, Volume: 29, Issue: 1	1999
Rational treatment of panic disorder with antidepressants. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, Volume: 10, Issue: 4	1998
Panic disorder: long-term pharmacotherapy and discontinuation. Journal of clinical psychopharmacology, Volume: 18, Issue: 6 Suppl 2	1998
Clinical pharmacokinetics of acamprosate. Clinical pharmacokinetics, Volume: 35, Issue: 5	1998
Enhancement of immobility in mouse forced swimming test by treatment with human interferon. European journal of pharmacology, Aug-28, Volume: 356, Issue: 1	1998
Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway. Journal of neurochemistry, Volume: 71, Issue: 4	1998
[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse (New York, N.Y.), Volume: 30, Issue: 1	1998
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. The Journal of clinical psychiatry, Volume: 59, Issue: 2	1998
Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacology, biochemistry, and behavior, Volume: 58, Issue: 4	1997
Acute lung failure induced by tricyclic antidepressants. Toxicology and applied pharmacology, Volume: 146, Issue: 2	1997
The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical pharmacology and therapeutics, Volume: 62, Issue: 2	1997
A computer model and program for xenobiotic disposition during pregnancy. Computer methods and programs in biomedicine, Volume: 53, Issue: 3	1997
[A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, Volume: 17, Issue: 2	1997
Suppression of the rat micturition reflex by imipramine. Journal of autonomic pharmacology, Volume: 17, Issue: 1	1997
Strategies for treatment of generalized anxiety in the primary care setting. The Journal of clinical psychiatry, Volume: 58 Suppl 3	1997
Voltammetric determination of imipramine hydrochloride and amitriptyline hydrochloride using a polymer-modified carbon paste electrode. Journal of pharmaceutical and biomedical analysis, Volume: 15, Issue: 3	1996
A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology, Volume: 127, Issue: 3	1996
Dosing issues in the pharmacotherapy of alcoholism. Alcoholism, clinical and experimental research, Volume: 20, Issue: 7 Suppl	1996
Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. Journal of lipid research, Volume: 37, Issue: 7	1996
Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding. European journal of pharmacology, Jun-03, Volume: 305, Issue: 1-3	1996
Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, Volume: 57, Issue: 6	1996
Recovery after 5 years of unremitting major depressive disorder. Archives of general psychiatry, Volume: 53, Issue: 9	1996
ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, Volume: 41, Issue: 2	1996
Second-order derivative spectrophotometric assay for imipramine hydrochloride and diazepam in pure admixtures and in dosage forms. Journal of pharmaceutical and biomedical analysis, Volume: 13, Issue: 8	1995
Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Molecular pharmacology, Volume: 43, Issue: 5	1993
Imipramine treatment of alcoholism with comorbid depression. The American journal of psychiatry, Volume: 150, Issue: 6	1993
Fluoxetine treatment of trichotillomania and depression in a prepubertal child. Cutis, Volume: 51, Issue: 1	1993
Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Therapeutic drug monitoring, Volume: 15, Issue: 3	1993
Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. International journal of clinical pharmacology research, Volume: 13, Issue: 3	1993
Effects of chronic imipramine on exploration, locomotion, and food/water intake in rats. Pharmacology, biochemistry, and behavior, Volume: 47, Issue: 3	1994
Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm. Journal of clinical psychopharmacology, Volume: 14, Issue: 2	1994
Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. The Journal of pharmacology and experimental therapeutics, Volume: 269, Issue: 1	1994
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. Journal of psychiatry & neuroscience : JPN, Volume: 19, Issue: 1	1994
Plasma levels and efficacy of imipramine treatment for enuresis. Journal of the American Academy of Child and Adolescent Psychiatry, Volume: 33, Issue: 1	1994
A double-blind comparison of nefazodone, imipramine, and placebo in major depression. The Journal of clinical psychiatry, Volume: 55, Issue: 6	1994
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. The Journal of clinical psychiatry, Volume: 55, Issue: 3	1994
Correct titration of non-drugs and some other methodological issues. Neuropsychobiology, Volume: 30, Issue: 1	1994
Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine. Clinical neuropharmacology, Volume: 17 Suppl 1	1994
Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. Journal of geriatric psychiatry and neurology, Volume: 7 Suppl 1	1994
Design of a desipramine dosing regimen for the rapid induction and maintenance of maximal cortical beta-adrenoceptor downregulation. Neuropharmacology, Volume: 33, Issue: 9	1994
Dose-response characterization of the antipanic effects of imipramine. Psychopharmacology bulletin, Volume: 30, Issue: 2	1994
Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. The American journal of psychiatry, Volume: 152, Issue: 5	1995
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. Acta psychiatrica Scandinavica. Supplementum, Volume: 386	1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Chromatographic studies of drug interactions with alpha Journal of chromatography. A, May-12, Volume: 1497	2017
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, May-24, Volume: 55, Issue: 10	2012
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry, Jul-14, Volume: 54, Issue: 13	2011
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. Journal of anesthesia, Volume: 24, Issue: 3	2010
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug metabolism and disposition: the biological fate of chemicals, Volume: 38, Issue: 1	2010
Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry. Journal of mass spectrometry : JMS, Volume: 44, Issue: 1	2009
Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Cognitive behaviour therapy, Volume: 37, Issue: 3	2008
Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 378, Issue: 1	2008
UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & therapeutics, Volume: 106, Issue: 1	2005
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug metabolism and disposition: the biological fate of chemicals, Volume: 31, Issue: 5	2003
The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicology and applied pharmacology, Jul-15, Volume: 158, Issue: 2	1999
Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet (London, England), Jan-31, Volume: 351, Issue: 9099	1998
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clinical pharmacokinetics, Volume: 29 Suppl 1	1995
Awareness and experience of general practitioners of selected drug interactions. British medical journal, May-04, Volume: 2, Issue: 5913	1974
Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man. British journal of pharmacology, Volume: 44, Issue: 1	1972
A double blind study in out-patients with primary non-agitated depression treated with imipramine in combination with placebo, diazepam or dixyrazine. Acta psychiatrica Scandinavica, Volume: 72, Issue: 4	1985
An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clinical pharmacology and therapeutics, Volume: 42, Issue: 4	1987
[Drug interaction of imipramine hydrochloride to the pharmacodynamics and pharmacokinetics of oxazepam]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, Volume: 90, Issue: 3	1987
[Drug interaction between imipramine hydrochloride and benzodiazepines when administered orally for 15 days]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, Volume: 91, Issue: 1	1988
Temperature dependence of drug interaction with the platelet 5-hydroxytryptamine transporter: a clue to the imipramine selectivity paradox. Journal of neurochemistry, Volume: 48, Issue: 2	1987
Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine. Acta psychiatrica Scandinavica, Volume: 75, Issue: 4	1987
Differences in the temperature dependence of drug interaction with the noradrenaline and serotonin transporters. Neuropharmacology, Volume: 28, Issue: 8	1989
Effect of lithium carbonate administration singly or in combination with some psychotropic drugs on the radioiodide uptake by mouse thyroid. Journal of pharmacobio-dynamics, Volume: 12, Issue: 8	1989
Oxypertine in combination with imipramine: a controlled trial. The Journal of international medical research, Volume: 6, Issue: 1	1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Intervention	units on a scale (Mean)
Bupropion	2.65
Escitalopram	2.73
Imipramine	2.67

Intervention	units on a scale (Mean)
Bupropion	11.2
Escitalopram	9.7
Imipramine	11.3

Intervention	Participants (Count of Participants)
Fluoxetine	7
Imipramine	4

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
chlorpromazine	[no description available]	high	978	47	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpromazine	[no description available]	high	978	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
clozapine	[no description available]	high	89	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
cyclindole	[no description available]	medium	1	0
flucindole	[no description available]	medium	1	0
amitriptyline	[no description available]	high	1,253	98	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amitriptyline	[no description available]	high	1,253	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
desipramine	[no description available]	high	1,265	71	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
desipramine	[no description available]	high	1,265	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
morphine chloride	[no description available]	medium	1	0	hydrochloride
clomipramine	[no description available]	high	322	24	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clomipramine	[no description available]	high	322	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
venlafaxine	[no description available]	medium	18	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
desvenlafaxine	[no description available]	medium	2	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
citalopram	[no description available]	medium	203	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
citalopram	[no description available]	medium	203	4	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
fluoxetine	[no description available]	medium	406	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
fluoxetine	[no description available]	medium	406	44	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
paroxetine	[no description available]	high	208	43	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
paroxetine	[no description available]	high	208	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
femoxetine	[no description available]	medium	3	0	piperidines
femoxetine	[no description available]	medium	3	1	piperidines
caffeine	[no description available]	medium	122	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
caffeine	[no description available]	medium	122	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
cgs 15943	[no description available]	medium	1	0	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
1-methyl-3-isobutylxanthine	[no description available]	medium	8	0	3-isobutyl-1-methylxanthine
rolipram	[no description available]	high	17	3	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
rolipram	[no description available]	high	17	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
adenosine	[no description available]	medium	13	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
phenylisopropyladenosine	[no description available]	medium	2	0	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
n(6)-phenyladenosine	[no description available]	medium	1	0	purine nucleoside
cp 66713	[no description available]	medium	1	0
heart	[no description available]	medium	1	0
adenosine-5'-(n-ethylcarboxamide)	[no description available]	medium	8	0	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
n(6)-cyclopentyladenosine	[no description available]	medium	1	0
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer	[no description available]	medium	1	0
n(6)-cyclohexyladenosine	[no description available]	medium	1	0
nomifensine	[no description available]	medium	91	0	isoquinolines	dopamine uptake inhibitor
nomifensine	[no description available]	medium	91	24	isoquinolines	dopamine uptake inhibitor
dextroamphetamine	[no description available]	high	166	11	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent

imipramine

Description

Cross-References

Synonyms (210)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (3)

Drug Classes (1)

Pathways (3)

Protein Targets (131)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (627)

Molecular Functions (206)

Ceullar Components (120)

Bioassays (919)

Research

Studies (9,485)

Study Types

Clinical Trials (34)

Trial Overview

Trial Outcomes

Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG

Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry

Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.

Clinical Global Impression Scale (CGI)

Hamilton Depression Scale (HAM-D)

Bioequivalence Determined by Statistical Comparison Cmax

Hamilton Depression Scale (HAM-D)

Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)

Anal Opening Pressure (AOP)

Urethral Opening Pressure (UOP)

Related Drugs (4,345)

Related Conditions (4,821)

Research Highlights

Safety/Toxicity (84)

Long-term Use (211)

Pharmacokinetics (88)

Onset of Action (1)

Bioavailability (41)

Dosage (296)

Interactions (25)